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ABSTRACT 
 
 The objectives of this thesis are to produce radioactive antibody-conjugated gold 
nanoparticles to improve the efficacy of targeted radionuclide therapy for the treatment 
of cancer, and to demonstrate that this product can be produced at Texas A&M 
University. 
We have proposed a method for determining the distribution of radioactive nuclei 
per nanoparticle, which is critical for determining radiotherapeutic efficacy.  Using the 
distribution of radioactive nuclei per nanoparticle, we have produced methods for 
calculating the radiative dose to tissue using nano-improved targeted radionuclide 
therapy, but more importantly we propose procedures to experimentally determine the 
efficacy of targeted radionuclide therapy improved by application of radioactive 
nanomaterials in combination with immunotherapy, nanomaterial cytotoxicity, and other 
cancer therapies such as chemotherapy.  These methods can also be used to determine 
the efficacy of combinatory treatments as a function of time. 
Characterization of the antibody-nanoparticle attachment is critical; we have 
demonstrated successful antibody-nanoparticle conjugation using atomic force 
microscopy, dynamic light scattering, and agarose gel electrophoresis, providing more 
conclusive evidence of successful conjugation compared to flow cytometry. 
We provide a mathematical derivation from basic electron-transport principles 
which demonstrates the theoretical dosimetric advantages of applying radioactive 
nanomaterials to targeted radionuclide therapy.  The general formulae can be applied to 
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any tumor size, any radionuclide, and any pharmacokinetic nanoparticle distribution 
throughout the body, ultimately allowing a quick method of approximating the necessary 
activation time and treatment dosage parameters for a specific patient without 
burdensome Monte Carlo computational simulations. 
We further demonstrated that nano-TRT dosage to tumors should be considered 
as a function of radial position rather than average, as the dose across the tumor may be 
noticeably non-uniform causing some portions of the tumor to receive (potentially) 
significantly less dose than average.  
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NOMENCLATURE 
 
A0   Saturation Activity 
AB   Activity of Isotope “B” (
198
Au) at Time = tirr + td 
AFM  Atomic Force Microscopy 
ATCC  American Type Culture Collection 
AuNPs  Gold Nanoparticles 
Bq  Becquerel 
CD  Cluster of Differentiation 
Ci  Curie 
CoA  Certificate of Analysis 
DLS  Dynamic Light Scattering 
EGFR  Epidermal Growth Factor Receptor 
Fab Region Fragment Antigen-Binding Region (Antibody) 
Fc Region Fragment Crystallizable Region (Antibody) 
FDA  Food and Drug Administration 
FRET  Förster Resonance Energy Transfer 
GBM  Glioblastoma Multiforme 
HER2  Human Epidermal Growth Factor Receptor Type 2 
HPGe  High Purity Germanium Detector 
I∞   Resonance Integral 
IARC  International Agency for Research on Cancer 
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IMRT  Intensity Modulated Radiation Therapy 
k   Mean Number of 
198
Au Nuclei per AuNP 
kD  Kilodalton 
LET  Linear Energy Transfer 
mAb  Monoclonal Antibody 
MRI  Magnetic Resonance Imaging 
MURR University of Missouri Research Reactor 
NA   Number of Nuclei of Isotope “A” (
197
Au) 
NAA  Neutron Activation Analysis 
NCI  National Cancer Institute 
NHS  N-hydroxysuccinimide  
NHL  Non-Hodgkin’s Lymphoma 
NIH  National Institutes of Health 
NIST  National Institute of Standards and Technology 
NSC  Nuclear Science Center (Texas A&M University) 
P  Probability of Randomly Selecting an AuNP with “λ” 198Au Nuclei from 
a Population of AuNPs whose Average Number of 
198Au is “k” 
PBS  Phosphate Buffered Saline 
PDF  Probability Distribution Function 
PDI  Polydispersity Index 
PE  R-phycoerythrin 
QC  Quality Control 
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RCF  Relative Centrifugal Force 
RPDF  Relative Probability Distribution Function 
SEER  Surveillance Epidemiology and End Results 
SPR  Surface Plasmon Resonance 
TAE  Triethanolamine Buffer 
TAMU Texas A&M University 
td   Decay Time After Irradiation 
TEM  Transmission Electron Microscopy 
tirr  Irradiation Time 
TRT  Targeted Radionuclide Therapy 
XRT  External Beam Radiation Therapy 
λ   Number of 198Au Nuclei in a AuNP 
σ2200   2200 m/s Cross Section 
σs  Neutron Scattering Cross Section 
ϕ2200   2200 m/s Neutron Flux 
ϕepi   Epithermal Neutron Flux 
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1. INTRODUCTION 
 
 The 2012 Surveillance Epidemiology and End Results (SEER) report published 
by the National Cancer Institute (NCI) estimates that 848,170 men, and 790,740 women 
in the United States of America will be diagnosed with some form of cancer in 2012, and 
577,190 people will die of cancer [1].  Common cancer treatments include 
chemotherapy, surgery, brachytherapy, and external beam radiation therapy (XRT).  
These treatments are not ideal, as they either do not discriminate healthy tissue from 
cancerous tissue (i.e. chemotherapy), or are confined to and treat only a small area of 
tissue (i.e. surgery or XRT).  More effective, more targeted treatment options are 
necessary for patients afflicted with cancerous minimal residual disease or disseminated 
cancerous disease, as these conditions cannot be treated effectively by focusing on one 
portion of the body, nor by treating the entire body (and therefore subjecting the entire 
body to potentially lethal doses of treatment). 
 
1.1 Targeted Radionuclide Therapy 
Targeted radionuclide therapy (TRT) is attractive in that radioactive materials are 
designed to seek and destroy molecular and functional targets in the patient’s cancerous 
tissue, augmenting the lethality to cancerous tissue while greatly reducing the effects to 
healthy surrounding tissue (see Figure 1.1 highlighting the tissues affected by radiation).  
TRT uses a targeting agent to transport a radioactive short-ranged nuclide to cancerous 
tissue.  Monoclonal antibodies (mAbs), for example, are synthesized by identical 
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immune cells and are clones of the same parent cell.  For this reason, mAb can be used 
to guide cancer treatment agents, since they preferentially bind to cancer cell-specific 
receptors.   
 
 
Fig. 1.1:  Comparison between Tissue Affected by Radiation (yellow) in XRT (a) vs. 
TRT (b) [2] 
 
A cancer may overexpress cell surface molecules known as clusters of 
differentiation (CD), which act as receptors or ligands.  These CDs are unique to certain 
cancer tissues, and can be used as targets for mAb-based therapies [3].  By using α or β- 
emitting radionuclides, which travel a short distance in human tissue in comparison to 
photons, radiative emissions will traverse and damage cancerous tissue and stop only 
microns to millimeters in surrounding healthy tissue.  The effectiveness of TRT is 
primarily dependent upon three factors [4, 5]: 
1. The affinity for the mAb to bind with tumor cells. 
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2. The physical and chemical characteristics of the radionuclide/mAb.  These 
include factors such as the radionuclide physical half-life, the mAb biological 
half-life and retention time, the mAb uptake rate, and the rejection rate of 
mAb from tissues. 
3. Treatment planning and administration.  The effectiveness of TRT is a strong 
function of the choice of radionuclide, as well as type and dosage of other 
treatments used in combination with TRT. 
Diseases for which TRT may be particularly effective include leukemias, 
lymphomas, cancerous metastases, and cancers which have invaded the body’s lymph 
nodes.  Two current examples of TRT treatments in the United States approved by the 
US Food and Drug Administration (FDA) are Zevalin and Bexxar [6].  These 
medications both treat non-Hodgkin’s Lymphoma (NHL) by combining a beta-emitting 
radionuclide (
90
Y for Zevalin, 
131
I for Bexxar) and a mAb designed to attach to the 
CD20-positive receptor of afflicted cells.  Though this new generation of monoclonal 
antibody-based therapies directly targets tumor cells, further research is necessary to 
increase the efficacy of these treatments.  Many methods of TRT enhancement are 
currently under investigation, including augmentation of effector functions, direct and 
indirect arming, delaying mAb decomposition, and pre-targeting of radionuclides [7]. 
 
 
 
  
 
 
 
4 
 
1.2 Medical Applications of Nanotechnology 
 Recent advances allow the synthesis of materials with one or more dimensions 
on the nanometer scale that can be used to treat or diagnose human diseases.  The field 
of nanomedicine can, in fact, be defined as the design and implementation of 
nanomaterials to improve detection, treatment, and monitoring of disease.  Since 
nanomaterials can be designed to perform multiple simultaneous biochemical functions 
at the nanometer scale, nanomedicine has become the focus of many research efforts, 
especially for the diagnosis and treatment of cancer [8].   
One recent application of nanomedicine is the variation in photon interaction 
cross sections for nanoparticles depending on the particle size.  Metallic materials have 
electrons which do not have to overcome a Fermi Gap to move from the valence band to 
the conduction band, shown below in Figure 1.2.   
 
 
Fig. 1.2:  Band Structure of Metal (Left) Materials [9] 
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When metallic nanoparticles are bombarded with electromagnetic radiation, the 
electron cloud can respond by oscillating in the constrained nano-scale structure in one 
large cohesive group.  These collective oscillations of the nanoparticle electron cloud 
induced by electromagnetic waves can dramatically affect the material’s photon 
interaction cross sections, a phenomenon known as surface plasmon resonance (SPR) 
[10].  Figure 1.3 illustrates SPR below, where the purple line represents the electric field 
component of the Poynting vector, the dark blue circles represent the physical metal 
nanoparticle, and the light blue represents the nanoparticle electron cloud responding to 
the incident oscillating electromagnetic field. 
 
 
Fig. 1.3:  Illustration of Nanoparticle SPR [11] 
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Binding a suitable nanoparticle with certain proteins and exciting the system with 
the appropriate wavelength of light yields a phenomenon known as Förster resonance 
energy transfer (FRET); the nanoparticle (aka “donor”) absorbs the incident photon and 
transfers the energy to its bound fluorophore (aka “acceptor”) via virtual photon energy 
transfer, which then emits the energy in the form of a photon [12].  Figures 1.4 and 1.5 
below illustrate the FRET process, as well as the resulting absorption/emission spectra.  
FRET can be used to amplify extremely faint signals in real-time with high spatial 
resolution, and could potentially be useful for characterizing the nanomaterials involved 
in this research [13-17]. 
  
 
 
 
7 
 
 
Fig. 1.4: Illustration of FRET 
 
 
Fig. 1.5:  Example FRET Absorption/Emission Spectra 
  
FRET 
Incident Excitation Photon 
 
 
 
 
AuNP (donor) Fluorophore (acceptor) 
Emission 
 
 
 
8 
 
In addition to nanoparticle-photon interactions, iron oxide nanoparticles are used 
as contrast agents in magnetic resonance imaging (MRI) exams due to their ability to 
change spin-spin relaxation times of neighboring water molecules, thereby enhancing the 
signal to noise ratio to provide clearer diagnostic images of the patient [18].  
Biodegradable nanoparticles have been developed recently as drug carriers to administer 
a range of drugs to varying parts of the body for sustained periods of time [19].  Single-
walled carbon nanotubes were recently used to transport cancer treatment into effected 
tissues using near-infrared radiative stimulation [20].  Magnetic nanoparticles can be 
subjected to an AC magnetic field, causing them to heat up within a patient’s tumor 
tissue to induce hyperthermia that has been shown to enhance the therapeutic effect of 
cancer treatments such as XRT [21].  Though biochemical applications of nanomedicine 
are under intense investigation, further research is necessary to develop and improve 
radiotherapy. 
 
1.3 Paradigm Shift - Improving TRT Using Nuclear Nanotechnology 
Novel cancer treatments could be invented by merging radiation therapy with 
nanotechnology.  Several recent studies demonstrated that injecting gold nanoparticles 
directly into cancerous tissue during XRT augments therapeutic effects due to the 
nanoparticles’  high photoelectric interaction cross section [22-25].  In 2010, Polf et al. 
demonstrated that injecting gold nanoparticles into tumor tissue also enhances external 
proton beam therapy [26].  Al though this gold nanoparticle injection technique is 
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promising for enhancing external beam therapies, these treatments remain localized to 
known tumor tissue, and still subject healthy tissue to ionizing radiation. 
The fundamental objective of this research is to augment TRT effectiveness and 
reduce potential side effects by merging nanotechnology with TRT.  Radioactive 
nanoparticles functionalized to target specific receptors of cancerous tissues via mAb 
conjugation will be studied for use in cancer therapy.  By introducing radioactive 
nanoparticles as radioactive payload carriers, the TRT treatment should be enhanced 
because the number of radioactive atoms per tumor cell is increased as shown below in 
Figure 1.6.  Furthermore, by separating the radionuclide from the mAb, it may be 
possible to improve TRT pharmacokinetics by avoiding radiolysis and decomposition of 
the antibody.  In 2006, Katti et. al. demonstrated that radioactive gold nanoparticles can 
be coated to yield greater than 80% uptake in mice liver cells with minimal 
accumulation in blood and other non-target tissues, which supports this hypothesis [27]. 
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Fig. 1.6:  Illustration of TRT (top) vs. Nano-Improved TRT (bottom) 
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The radionuclide used in the present research is 
198
Au.  Nanoparticles containing 
198
Au can be produced by a variety of ways [28].  For this research, we produced 
198
AuNPs by neutron activation of natural gold nanoparticles in a nuclear reactor.  
Equation 1.1 below describes this process. 
 
                                    (Eq. 1.1) 
        
      
      
      
 
 The typical nuclear decay reaction of 
198
Au is shown in Equation 1.2 (see Figure 
1.7 below for the decay chain of 
198
Au).  
198Au decays by β- emission.  This emission 
provides therapeutic effect by damaging cancerous tissue as it loses kinetic energy 
traveling through it.  The nuclide has a half-life of approximately 2.69 days and a 100% 
chance per decay to emit a β- particle; the average β- energy is about  312.4 keV (recall 
that the antineutrino carries away an average of about 2/3 of the total energy).   
 
                       (Eq. 1.2) 
    
      
         ̅         
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Fig. 1.7:  
198
Au Decay Chain [29] 
 
The beta emission spectrum of 
198
Au is shown below in Figure 1.8.  The range in 
typical human tissue of the mean energy 
198Au β- emission is approximately 0.95 mm.  
This is a long enough path length to affect surrounding cancer cells which may under-
express the cancerous target receptor (a phenomenon sometimes called “cross-fire”), 
while sparing most surrounding healthy tissue and nearby organs from direct radiation 
insult.  95.6% of 
198Au decays are accompanied by a γ decay of about 411.8 keV that is 
easily detectable using appropriate gamma detection equipment.   
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Fig. 1.8:  
198
Au Beta Decay Spectrum [30] 
 
  Auger electrons can be released during 
198
Au decay with an average energy of 
about 15.1 keV.  Cancerous tissue can become radiosensitized by low-energy (tens of 
keV) electrons; thus these Auger electrons may further augment the effect of radiation 
therapy [31, 32].  This phenomenon is likely due to the high-LET nature of electrons in 
this lower energy regime [33]. However, only about 2.3% of 
198Au β- emissions are 
accompanied by the emission of an Auger electron, and will therefore be ignored. 
These gold nanoparticles (AuNPs) may also incorporate other therapeutic drugs 
as well.  Radiation therapy is often more effective when used in combination with one or 
more alternate treatment methods [32, 34].  By merging TRT with nanotechnology, it 
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may be possible to incorporate cytotoxic drugs into the TRT-nanoparticle for 
simultaneous radiochemical treatments, further augmenting therapeutic effect. 
 
1.4 Cancer Cell Line Investigated in This Study 
 Theoretically TRT can be applied to any type of cancer that overexpresses a 
known receptor for which a unique mAb may be synthesized.  SK-BR-3 (ATCC; HTB-
30
TM
) adenocarcinoma breast cancer tissue was the cell line of interest for this study.  
This cell line overexpresses the human epidermal growth factor receptor type 2 (HER2).  
According to the International Agency for Research on Cancer (IARC), an agency which 
is part of the World Health Organization of the United Nations, nearly 39% of cancers 
found in women are breast cancers, of which 20-30% dramatically overexpress HER2 
[1, 35, 36]. 
The HER2 receptor is one of four members of the epidermal growth factor 
receptor (EGFR) family (the others being HER1, HER3, and HER4).  The EGFR family 
is present in normal tissue (though they are not found in the abundance found in many 
cancer types), and plays important roles in cell differentiation, migration, wound healing, 
and other functions essential to cell survival [37].  Cells which mutate and over-express 
EGFRs rapidly multiply and become more resistant to apoptosis, driving the 
development and survival of these cancers.  HER1 is overexpressed in at least 50% of 
epithelial malignancies, and HER3 and HER4 are variably expressed in several types of 
cancers [38].  Subsequently, EGFR inhibitor research for the development of anticancer 
agents (including mAbs) has been active in the last twenty years [34]. 
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1.5 Nano-Improved TRT: Final Product Design 
 Trastuzumab (also known by its brand name as Herceptin) from Genentech is a 
humanized mAb which binds to the extracellular juxtamembrane domain of HER2 [35].  
In addition to providing a method of targeting HER2-overexpressed cancer tissue for 
selective nano-TRT treatment, Trastuzumab alone inhibits the survival and growth of 
these tumors through several possible processes including preventing the activation of 
intracellular tyrosine kinase, inhibiting extracellular domain shedding, immune 
activation, and ligand blocking [34, 35].  Herceptin was approved by the FDA in 1998, 
and has since been used to treat various HER2 cancers.  Unfortunately this medical-
grade product is quite expensive.  Alternatively, PE anti-human CD340 monoclonal 
antibody from Biolegend also targets the HER2 receptor but costs a fraction of 
Herceptin’s price.  This mAb is also tagged with the fluorophore R-phycoerythrin (PE), 
which will be discussed further in Section 2.10.  CD340 is a member of the EGFR 
family of cell membrane tyrosine kinases containing a single transmembrane domain and 
has a molecular weight of about 185 kD.  The final design shown below in Figure 1.9 is 
a nanoparticle with multiple radioactive atoms, coated with a stabilizing surfactant (to 
prevent AuNP agglomeration) with mAbs attached. 
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Fig. 1.9: Proposed Final Design, Complete with Radioactive AuNP Core and Attached 
mAbs  
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2. METHODS 
 
2.1 Preliminary Nanoparticle Properties and Characterization 
 We initially investigated two sets of gold nanoparticles from different vendors in 
this research.  One set had an average diameter of 17 nm, purchased from Nanopartz 
Inc., Salt Lake City, USA, while the other set had an average diameter of 10 nm from 
Cytodiagnostics Inc., Ontario, Canada.  The Nanopartz nanoparticles contained a 
concentration of 1.33x10
14
 particles mL
-1
 with a Certificate of Analysis (CoA) 
containing TEM, UV-VIS, and dynamic light scattering (DLS) measurements and 
calculations shown below in Table 2.1 and Table 2.2.  Figure 2.1 below shows a vendor-
provided TEM image of these gold nanoparticles prior to shipment.  The Nanopartz 
AuNPs were encased in a polymer with N-hydroxysuccinimide (NHS) ester terminal 
groups to protect the AuNPs from salt and variations in pH, as well as reduce non-
specific binding and aggregation.  The AuNPs were stored at 4 °C while not in use to 
maintain nanoparticle coating stability and prevent nanoparticle coagulation.  Nanopartz 
guaranteed directional conjugation whereas Cytodiagnostics initially did not.  The 
potential implications of this will be discussed later. 
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Table 2.1:  CoA Measured AuNP Characteristics (Nanopartz) 
  Measurement Method Units 
Measured 
Value 
 Avg. Diameter DLS, TEM, UV-VIS nm 17 
PDI DLS, TEM StdDev/size 7% 
SPR Abs. Peak UV-VIS nm 521 
Zeta Potential DLS mV -15 
 
 
Table 2.2: CoA Calculated AuNP Characteristics (Nanopartz) 
Characteristic Units Calculated Value 
Concentration NPs mL
-1
 1.33x10
14
 
Wt. Concentration mg mL
-1
 6 
ppm   6000 
Wt. % % 0.6000% 
Molarity μM 0.212133 
Molar Ext. M
-1 
cm
-1
 5.43x10
8
 
 
 
Fig. 2.1:  TEM Image of 17 nm AuNPs Upon Arrival (Nanopartz) 
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The AuNPs from Cytodiagnostics (shown in TEM below in Figure 2.2) were 
supplied at a particle density of 5.98x10
12
 AuNPs mL
-1
, and an SPR peak of 518 nm. 
 
 
Fig. 2.2:  TEM Image of 10 nm AuNPs upon Arrival (Cytodiagnostics)  
 
2.2 Neutron Activation Preparation 
 All gold nanoparticles were purchased as natural gold (
197
Au).  The AuNPs were 
made radioactive through the nuclear reaction shown in Equation 1.1.  We initially 
activated gold nanoparticles at the TAMU Nuclear Science Center (NSC).  Sample 
temperatures could reach as high as 80 °C, which is significantly lower than the 
temperatures required to cause thermal-induced gold structural changes such as thermal 
annealing [39].  We transferred samples of the nanoparticle solution into a quartz vial in 
preparation for neutron activation.  Quartz has excellent neutronic properties that allow 
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thermal neutrons to reach the gold nanoparticles without damaging the vial during 
irradiation, and has already been established as an effective vessel for activating gold 
nanoparticles in previous research efforts [40].  Quartz vials were sealed at the TAMU 
Department of Chemistry Glass Shop by freezing the quartz in liquid nitrogen and 
rapidly melting the tip shut with a blow torch.  The sealed vials are sealed in an 
aluminum can filled with aluminum foil during irradiation to protect the vial from 
damage during movement to and from the reactor core while still allowing neutrons to 
reach the nanoparticles within.  The prepared vial is shown below in Fig. 2.3. 
 
 
Fig. 2.3:  AuNP Neutron Activation Vial Assembly 
 After neutron activation, the quartz vials must be opened to extract the 
nanoparticles.  Initially we opened the quartz vial using a diamond-coated saw.  This 
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method resulted in contaminating the sample inside due to quartz dust from sawing 
through the vial.  Instead, we subsequently used a blow torch to melt a hole in the lid of 
the quartz. 
 
2.3 Neutron Activation Analysis 
 Neutron Activation Analysis (NAA) equations can be used to calculate the 
activity of a sample material which has been exposed to a neutron field for a given time.  
The fundamental equations for NAA, shown below in Equations 2.1 and 2.2, are valid 
assuming the neutron flux does not change throughout the activation, negligible burnup 
of daughter atoms, and negligible decrease of target atoms. 
 
                              (Eq. 2.1) 
  (       )    (   
       )       
 
                                   (Eq. 2.2) 
     (                 ) 
 
Although the total activity of the activated sample is a concern for dose to 
personnel handling the nanoparticles, the primary concern for therapeutic effect is not 
the total sample activity injected, but rather the number of radioactive atoms per 
nanoparticle.  This is discussed later in the section. 
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 To conduct high resolution gamma spectroscopy, we used a Model BE2020 
Canberra High Purity Germanium Detector (HPGe) provided by TAMU Nuclear 
Engineering Professor Dr. Craig Marianno.  The total activity of the samples was on the 
order of several hundreds of µCi.  Such a high activity source could yield significant 
detector dead time.  To avoid this, the detector and source were placed 2.8 meters apart 
(± 1 mm), significantly reducing the solid angle of emissions from the source to the 
detector. 
 To ensure that the Genie2000 software associated with the HPGe was applying 
geometry calculations properly, we used a calibration method involving a known gold 
source.  Since 
198
Au only has a half-life of 2.69 days, we had to produce this known 
radioactive gold source for every nanoparticle activation trial.  We purchased NIST-
certified FLUKA Gold Standard Solution from Sigma-Aldrich for which the gold 
concentration was known.  For each activation experiment, the nanoparticle vial was 
accompanied by a second vial of the Gold Standard solution, both of which had the same 
geometry and was activated simultaneously.  Given known reactor conditions, the gold 
standard activity can be calculated using NAA equations, which provided us with a 
reasonably accurate calibration standard to measure the nanoparticle sample activity. 
 
2.4 Radioactive Nanoparticle Structural Integrity 
 Neutron activation can degrade structural integrity of the nanoparticles and their 
coatings; to monitor integrity we used transmission electron microscopy (TEM).  TEM is 
ideal for imaging AuNPs because of the metal’s high density and ability to scatter 
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electrons.  For this experiment, we used the JEOL JEM-2010 TEM at the TAMU 
Microscopy & Imaging Center.  Using the images from this analysis, we could 
quantitatively characterize the size of nanoparticles, including mean diameter, standard 
deviation, maximum and minimum sizes, etc.  The open-source program, ImageJ, 
developed by the National Institutes of Health (NIH), is well suited for this analysis.  
Note that AuNP-mAb conjugation must occur after neutron activation, as the antibodies 
and/or bindings will likely not survive the radiation fields they would experience during 
the activation process. 
 
2.5 Nuclear Probability Theory: Radioactive Nuclei per Nanoparticle 
 Each nanoparticle must contain at least one radioactive atom to yield any 
potential radiotherapeutic effect, therefore the distribution of radioactive atoms among 
the nanoparticles in the sample should be known.  The total sample activity and the 
number of radioactive atoms per nanoparticle are dependent on irradiation and decay 
time, as well as the neutron flux in the reactor.  Even using the same activation 
conditions, however, the number of radioactive atoms per nanoparticle is a function of 
the size of the nanoparticle, because larger nanoparticles contain more 
197
Au nuclei and 
therefore more potential activations.   
The statistical Poisson Distribution applies when: (1) the event of interest (i.e. a 
197
Au nucleus absorbs a neutron) can be counted in discrete whole numbers, (2) 
occurrences are independent such that one occurrence does not diminish nor increase the 
probability of another, (3) the average frequency of the occurrence is known, and (4) it is 
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possible to count how many events have occurred.  Since the total decrease of 
197
Au 
nuclei from the population due to neutron absorption during activation is negligible, it is 
reasonable to approximate the above four parameters are met.  The number of 
198
Au 
nuclei per nanoparticle can therefore be calculated using the Poisson Distribution, shown 
below in Equation 2.3.  Assuming a 12 hour irradiation and 6 hours of decay in the NSC 
nuclear reactor for both trials, the following “198Au nuclei per nanoparticle” distributions 
in Figure 2.4 show a clear comparison when using 10 nm vs. 17 nm diameter 
nanoparticles. 
 
                            (Eq. 2.3) 
 (   )  
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Fig. 2.4:  Poisson Distribution of Calculated 
198
Au Nuclei per AuNP Given tirr = 12 h (in 
TAMU NSC Reactor) and td = 6 h, 10 nm vs. 17 nm 
 
 Under the given activation conditions, nearly 18% of the 10 nm nanoparticles 
contain no radioactive nuclei; thus, nearly 18% of these nanoparticles yield no TRT 
effect.  Almost all of the 17 nm AuNPs, however, contain at least one 
198
Au nucleus.  
Under these irradiation conditions, the 10-nm sample has an average of about 1 
radioactive nucleus per nanoparticle, whereas the 17-nm sample has an average of about 
8 radioactive nuclei per nanoparticle. 
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2.6 Nanoparticle-Antibody Directional Conjugation 
 Two major concerns when conjugating nanoparticles with antibodies are the 
weak non-covalent antibody attachment to nanoparticles and the potentially random 
orientation of bound antibodies to the gold nanoparticle surface due to their electrostatic 
interactions [41].  A weak antibody-ligand bond may lead to antibody replacement by 
other molecules, while randomly oriented antibodies bound to ligands may significantly 
reduce the likelihood of antibody-cell interaction.  Nanopartz Inc. coats nanoparticles 
with a proprietary ligand which covalently bonds specifically with the fragment 
crystallizable (Fc) region of the antibody.  This directional conjugation is critical, as the 
fragment antigen-binding (Fab) region of the mAb is responsible for interacting with the 
cancer cells’ receptors, and small (~10 nm) AuNPs will likely have only a few 
antibodies attached per nanoparticle.  This can be visualized from Figures 2.5 and 2.6 
below. 
 
 
Fig. 2.5:  Antibody Schematic with (Top) the Fab Region, and (Bottom) the Fc Region 
[42] 
 
 
 
27 
 
 
Fig. 2.6:  Antibody-Cell Attachment Schematic with Fab-Receptor Interaction 
 
 The procedure to directionally conjugate the Nanopartz nanoparticles is as 
follows.  Non-potassium containing phosphate buffered saline (PBS) from Thermo 
Pierce (# 28372) was used as a conjugation buffer.  Gold nanoparticles were added to the 
CD340 in PBS with a mAb:AuNP molar ratio of approximately 500:1 and placed in a 
vortex machine for 1 to increase the rate at which mAbs interact with AuNPs, thereby 
increasing the rate of conjugation.  The mAb:AuNP ratio is sufficiently large such that 
nearly all AuNPs have attached mAbs, bypassing the need to separate the conjugated 
and unconjugated AuNPs.  The supernatant was then removed by centrifuging for 30 
minutes at 12,000 relative centrifugal force (RCF).  Conjugated AuNPs are stored in 
pure water at 4 °C. 
 Throughout this thesis AuNPs from Cytodiagnostics are referred to as “bare” 
since they are not coated with materials which drive directional mAb conjugation.  In 
reality, the AuNPs from Cytodiagnostics are coated with the stabilizing surfactant 
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trisodium citrate (Na3C6H5O7).  This surfactant reduces the degree of AuNP 
agglomeration and does not drive conjugation. 
 
2.7 Conjugated Nanoparticle Characterization 
 There are several methods to determine the direction and density of mAb 
attachment to the AuNPs.  A FRET technique, discussed in Chapter 1.2, was initially 
conceived, which could be collected using flow cytometry.  We realized that additional 
data would be available through agarose gel electrophoresis from the suggestion of Dr. 
Mahmoud El Sabahy, Co-Assistant Director of the TAMU Laboratory for Synthetic-
Biological Interactions.  With proper control groups, gel electrophoresis can provide 
strong evidence of mAb conjugation due to the distinct migration of particles based on 
charge and size [43, 44].  We conducted electrophoresis using BIO-RAD gel 
electrophoresis equipment with a 100 V driving potential for 1 hour.  The agarose gel 
was prepared by heating 400 mL of pure water [with 6 mL of triethanolamine (TAE) 50x 
buffer (pH of 8.3)] to boiling.  Once boiling, 3 g of agarose powder was added and 
boiling continued until the powder was dissolved.  The mixture was heated with stirring 
until the final volume was 300 mL, and then allowed to cool until warm to the touch.  
The solution was poured into the mold and allowed to set for approximately 45 minutes.  
The gel was then transferred to the BIO-RAD electrophoresis template and filled with 
the buffer solution, prepared by adding 20 mL of TAE buffer to 980 mL of triple-
distilled water. 
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Besides electrophoresis, dynamic light scattering (DLS) measurements can 
provide evidence of mAb attachment [45-47].  Nanoparticles suspended in solution 
experience Brownian motion, which causes fluctuations in light scattering intensity 
during laser stimulation.  These fluctuations can provide information such as particle 
size distribution, polydispersity, and zeta potential of the sample [48].  These values 
should change if conjugation is successful.  The DLS instrument used, provided by 
TAMU Professor Dr. Karen Wooley, was the Delsa Nano C Particle Analyzer from 
Beckman Coulter. 
While the above techniques yield macroscopic information representing a 
population of AuNPs, individual AuNP characterization is also necessary [49].  TEM is 
ineffective for imaging mAb-conjugated AuNPs for several reasons.  The kinetics 
associated with the high energy/intensity electron beam may dissociate the attachment 
between the nanoparticle and the antibodies.  The high vacuum conditions inside the 
TEM may also destroy these bonds.  Most important, however, proteins generally scatter 
energetic electrons with very low efficiency.  While the metal nanoparticles can be seen 
clearly in TEM, the signal from any proteins will be indistinguishably faint.  However, 
atomic force microscopy (AFM) is a viable alternative.  AFM generally has resolution 
on the order of fractions of a nanometer, and is capable of generating 3-dimensional 
images of nanomaterials (a capability which TEM generally cannot do).  The instrument 
operates by scanning the surface of a specimen with a sharp-tipped probe connected to a 
cantilever (shown below in Figure 2.7).  As the tip passes over a different material (for 
example, going from substrate to a nanoparticle), the tip is deflected vertically.  This 
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deflection is measured by reflecting a laser beam from the top surface of the cantilever 
into a photodiode array (see Figure 2.8).  It may be possible to confirm mAb-AuNP 
attachment by using AFM to image the nanoparticles before and after mAb conjugation.  
We collected images using the Bruker Multimode-8 Atomic Force Microscope under the 
supervision of the TAMU Laboratory for Synthetic-Biological Interactions Co-Assistant 
Director Dr. Jeffrey Raymond. 
 
 
Fig. 2.7:  AFM Cantilever and Pointed Tip [50] 
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Fig. 2.8:  Diagram of AFM Components [51] 
 
2.8 Radioactive Nanoparticle Dosimetry 
 TRT dosimetry is complex in comparison to XRT due to the pharmacokinetics 
associated with the radionuclide agents.  Assuming that all nanoparticles are conjugated 
with targeting agents (in this case CD340), there is no guarantee that 100% of 
conjugated AuNPs will encounter and bind to cancerous tissue; in fact recent studies 
have shown that the binding efficiency of Trastuzumab-conjugated AuNPs can be as low 
as 65% for large (>200 nm) nanoparticles [52].  By using smaller 150 nm nanoparticles, 
however, a recent study suggests that the presence of the nanoparticles may actually 
increase the likelihood of mAb-cell interaction by up to 25% [53].  If the conjugated 
AuNPs do encounter and interact with the cells, the nanoparticles will eventually be 
released from the cells (hence a biological half-life).  The whole-body biological half-
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life of Trastuzumab, however, has been shown to vary from 3-4 weeks, which is 
equivalent to 8-11 physical 
198
Au half-lives [54]. 
The following calculation assumes an infinite AuNP residence time within the 
target cell.  Assuming the same 12 hour neutron activation and 6 hour decay of 
nanoparticles, the 17 nm AuNPs will have an average of 8 radioactive nuclei per 
nanoparticle.  Given that the primary β- emission from 198Au yields 311 keV Bq-1 s-1 and 
assuming an infinite nanoparticle residence time within the cancerous tissue, a 
correlation between 17 nm AuNPs per cell vs. dose from the primary β- emission may be 
calculated directly, shown below in Figure 2.9.  This dose calculation approximates an 
infinite medium of cancer cells with a homogeneous distribution of radioactive 
nanoparticles such that, on average, as a β exits a cell, an identical one enters it.  This 
allows a quick estimation of dose by allowing us to assume that, effectively, all the β 
energy is deposited into a cell.  While studies show that hematopoietic malignancies 
such as NHL only require TRT doses as low as 15 Gy to observe significant therapeutic 
effects, solid tumors may require doses higher than 60 Gy [55]. 
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Fig. 2.9:  Calculated Dose (Gy) from Primary β- Emission vs. 17 nm AuNPs per Cell, 
Assuming Infinite AuNP Residence Time Approximation 
 
2.9 Cell Culture 
 Methods for the culture and maintenance of the SK-BR-3 cell line are available 
online via ATCC.  Imaged below in Figure 2.10 is cultured SK-BR-3 adenocarcinoma 
(before treatment). 
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Fig. 2.10:  Microscope Image of Cultured SK-BR-3 Adenocarcinoma Cells 
 
2.10 Flow Cytometry and Fluorescent Microscopic Analysis  
 The affinity with which conjugated nanoparticles bind to target cells is critical.  
Cell binding was assessed using the Accuri C6 Flow Cytometer, equipped with two 
excitation lasers that operate at wavelengths of 488 nm and 640 nm.  To complement the 
quantitative flow cytometer measurements, we collected fluorescent images using the 
Invitrogen FLoid
TM
 Cell Imaging Station from Life Technologies Corporation.  Flow 
cytometry provides a means of measuring physical and chemical properties of individual 
cells simultaneously (or other particles, such as mAbs or AuNPs) in a fluid stream at 
speeds on the order of tens of thousands of cells per second [56, 57].  For an illustration 
of how flow cytometry works, see Figure 2.11 below.  The instrument funnels particles 
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into a single-file stream.  The focused particles pass through and interact with laser 
beams.  Cells which express receptors unique to that cell type, such as HER2 for the case 
of SK-BR-3, may be bound with a mAb.  By using mAbs which are tagged with a 
fluorochrome, flow cytometry provides an effective means of determining whether the 
conjugated nanoparticles are attached to the cells. 
 
 
Fig. 2.11:  Flow Cytometer Operating Principles 
  
As cells pass through a laser beam, the mAbs fluoresce and scatter light in all 
directions.  Light scattered in the forward direction (i.e. deflected by a small angle) can 
be used to determine the size of the particle.  Scattering events at 90° to the incident 
laser beam can be used to determine cell cytosolic structure (e.g. inclusions or granules) 
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[58].  Fluorescence indicates the presence of a cell with fluorochrome-tagged antibodies.  
Cells that are bound with fluorochrome-containing antibodies can then be imaged with 
the fluorescent microscope.  This combination of instruments provides both quantitative 
and qualitative analysis of the interactions between the cancer cells and the antibodies 
that selectively seek and bind to them.  As mentioned in Section 1.5, the CD340 
antibodies are tagged with PE.  This fluorochrome’s absorption and emission spectrum 
are below in Figure 2.12. 
 
 
Fig. 2.12:  PE Absorption and Emission Spectra [59] 
 
2.11 Cell Characterization and Growth Response Analysis 
 Clonogenic Assays are typically used to determine radiation-induced cellular 
response.  However, there are two significant disadvantages associated with a clonogenic 
assay for the purposes of TRT-induced cellular response [60-63].  The first disadvantage 
 
 
 
37 
 
is one of impracticality; clonogenic assays are time consuming and require a large 
number of cells, antibodies, nanoparticles, etc.  More important, a traditional clonogenic 
assay inherently cannot determine cell response as a function of time. 
 Alternative to clonogenic assays is the xCELLigence System from Roche 
Applied Science [64-66].  This system monitors cell population in real time without the 
use of labels or probes by measuring the electrical impedance across an electrode array 
at the bottom of the tissue culture plates.  The dimensionless parameter “cell index” is 
derived as the relative change in impedance to represent cell status.  This provides a 
method of measuring cell number, viability, and morphology as a function of time.  In 
comparison to XRT, these real-time measurements are especially important for the 
purposes of TRT-induced cell response since the radiative emissions occur gradually 
over time rather than in one short burst. 
 The xCELLigence system operates while inside the incubator.  Since it measures 
cell characteristics over time, this system can provide quantitative data of cell growth 
and cell death on multiple samples and controls simultaneously.  A schematic of 
xCELLigence system functionality is shown below in Figure 2.13. 
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Fig. 2.13:  Illustration of xCELLigence System Impedance Variability due to Cell 
Adhesion [67] 
 
 An additional advantage to using this system is freedom in experimental control 
groups as a function of time.  For example, researchers have recently calculated the dose 
of radioactive nanoparticles to solid tumors with computational simulations that may 
predict biological effects [68-70].  However, simulations do not account for phenomena 
which influence radiation-induced biological effects, such as metal nanoparticle 
cytotoxicity.  As previously discussed, cancer therapy regimens often incorporate 
multiple kinds of treatments which can augment one another’s effectiveness [32, 34].  
These effects need to be assessed together to determine full treatment efficacy.  
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3. RESULTS AND DISCUSSION 
 
3.1 Small (10 nm & 17 nm Diameter) AuNP Failures 
 To determine surfactant longevity nanoparticles from both vendors were 
intentionally aged (at 4 °C) past their shelf life and tested until they failed.  Since 
Nanopartz guaranteed directional conjugation and Cytodiagnostics initially did not, these 
different coatings could have yielded different product shelf lives. 
The AuNP trisodium citrate stabilizer from Cytodiagnostics (see original TEM 
image Figure 2.2) consistently failed during 8- and 6-hour neutron activations in the 
NSC nuclear reactor; however non-activated samples from this batch were normal to the 
naked eye 9 months later.  In Fig. 3.1, the nanoparticles after neutron irradiation 
(middle) have clearly agglomerated into a closely packed group, leaving the water clear 
instead of the red hue before neutron activation (left).  The proprietary stabilizer from 
Nanopartz (see original TEM image Figure 2.1) failed without neutron activation after 5 
weeks of 4 °C storage.  The Nanopartz AuNPs adhered to the walls of the vial as shown 
below in Figure 3.1 (right). 
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Fig. 3.1:  10 nm Cytodiagnostics AuNPs Before (left) and after (middle) Activation, and 
5 Week Old Non-Activated 17 nm Nanopartz AuNPs (right) Adhering to Vial  
 
 After discussing the passive AuNP agglomeration with Nanopartz, the vendor 
sent an additional sample of nanoparticles suspended in phosphate buffered saline 
(PBS).  The AuNPs did not appear to coat the walls of the container as before.  Using the 
same preparation and sealing procedures discussed earlier, we activated a sample of the 
new Nanopartz 17nm AuNPs for 6 hours in the TAMU NSC reactor, and this surfactant 
also failed. 
 After the 6 hour activation and subsequent 47.5 hours of decaying in the NSC 
reactor pool, the sample had clearly agglomerated to the naked eye and appeared similar 
to that of Figure 3.1 (middle).  Had the nanoparticles survived, however, the distribution 
of 
198
Au nuclei per AuNP would be similar to that shown below in Figure 3.2.  
Activating 17 nm AuNPs for 6 hours in the NSC nuclear reactor will not produce the 
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goal of at least one radioactive atom per nanoparticle, even if the nanoparticles had not 
agglomerated.  Failure mechanisms and solutions to this issue are discussed in the next 
sections. 
 
 
Fig. 3.2:  Measured 
198
Au Nuclei per 17 nm Nanopartz AuNP (Had the AuNPs 
Survived) 
 
 Even though the non-activated nanoparticles in solution from Nanopartz 
appeared to be stable to the naked eye, the first sample (which passively failed far before 
the expiration date) combined with the failure of the recent activated sample invoked our 
curiosity as to how effective the current surfactant was.  We used AFM to attain 3D 
images and data for the new Nanopartz sample, both unconjugated (Figure 3.3) and 
0
5
10
15
20
25
30
0 5 10 15
P
ro
b
a
b
il
it
y
 (
%
) 
Measured "#" of 198Au Nuclei in an AuNP 
 
 
 
42 
 
conjugated with the PE CD-340 antibodies (Figure 3.4).  Several AFM images collected 
for this analysis are shown below. 
 
  
Fig. 3.3: 2D (Left) and 3D (Right) Images of Unconjugated 17 nm Nanopartz AuNPs 
 
  
Fig. 3.4: 2D (Left) and 3D (Right) Images of mAb-Conjugated 17 nm Nanopartz AuNPs 
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 The collection of images from this experiment yields two critical results.  First, 
the new sample of 17 nm AuNPs provided by Nanopartz was almost exclusively 
comprised of larger (>60 nm in all three dimensions) aggregates.  Since these 
nanoparticles had not yet been activated, had been stored in the proper 4 °C 
environment, and still had several months left on the predicted shelf life of three months 
provided by the manufacturer, we concluded that the surfactant used by Nanopartz is not 
effective in preventing nanoparticle agglomeration.  AFM spectral analysis revealed that 
the few unconjugated AuNPs were consistently 16-19 nm, whereas the conjugated 
AuNPs were consistently 22-25 nm.  These images provide strong evidence that our 
procedures to conjugate the nanoparticles were indeed successful. 
 After AFM, we looked at these AuNP samples using DLS.  The resulting 
hydrodynamic diameters by number of the bare and conjugated AuNPs were of little use 
due to severe AuNP agglomeration (40 ± 10 nm for bare, and 41 ± 10 nm for 
conjugated).  The zeta potential, which is simply the electrokinetic potential of colloidal 
systems used to determine coagulation potential, was -19 ± 2 mV for the bare sample 
and -28 ± 1 mV for the conjugated sample.  This further suggests that, although the 
Nanopartz AuNPs were aggregating, our attempts to conjugate remaining single AuNPs 
were successful. 
 The three primary methods to mitigate AuNP agglomeration during neutron 
activation are to reduce the amount of time the nanoparticles are subjected to the high 
temperature of the nuclear reactor, reduce the nanoparticle surface energy, and reduce 
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the gamma ray dose rate during activation.  These methods will be discussed in the 
following two sections. 
 
3.2 AuNP Agglomeration and Failure Mechanisms 
 As discussed, the Cytodiagnostics “bare AuNPs” are coated with the stabilizing 
surfactant trisodium citrate.  There are several mechanisms that may cause this surfactant 
to fail, thereby allowing nanoparticle aggregation to occur.  The AuNPs are activated 
while inside a sealed quartz vial (see Figure 2.3).  Recall that this vial is closed using 
liquid nitrogen and a high temperature flame.  If the vial is cooled too long with liquid 
nitrogen during sealing, the contents of the vial will freeze, bringing the AuNPs closer 
together and potentially compromising the stabilizing surfactant.  This failure 
mechanism did not occur during any of our tests.  Similarly, if the AuNPs are exposed to 
sufficiently high temperatures (for example those found in some nuclear reactors), the 
trisodium citrate surfactant will also fail.  The amount of time required to cause 
surfactant failure depends on temperature.  We tested the Cytodiagnostics surfactant in a 
90 °C water bath for 48 hours and observed negligible agglomeration, indicating that the 
high temperature environment of the NSC reactor did not drive agglomeration. 
 Radiation produced from the nuclear reactor core (primarily neutron and γ at the 
sample location) contribute to surfactant failure.  Any nucleus is capable of absorbing 
neutrons; however the nuclei which compose the trisodium citrate surfactant 
(Na3C6H5O7) all have extremely low probabilities to do so, shown below in Table 3.1 in 
comparison with natural gold.  Other neutron interactions with these nuclei dominate, 
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especially elastic scattering.  The thermal neutron elastic scattering cross section for 
1
H 
is approximately 20.5 barns; since the 
1
H nucleus has similar mass to a neutron, 
conservation of momentum requires that a “head-on” (0° neutron deflection angle) 
elastic neutron scattering transfers nearly all of its kinetic energy to the nucleus, which 
may be enough to remove the nucleus from the molecule.  Similar phenomena can occur 
with the other nuclei can occur, however, the scattering cross sections are smaller.  
Fissions occurring inside the reactor core also release γ radiation which can destroy the 
surfactant; however, γ exposure originating from outside the sample can be attenuated 
and reduced by surrounding the sample with a lead shield (which is more transparent to 
neutrons than γ’s). 
 The 
197Au nucleus releases a prompt γ upon neutron absorption, after which the 
resulting 
198Au nucleus can release a β and γ during radioactive decay.  Surfactant 
exposure from these radiations is unavoidable. 
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Table 3.1:  Neutron Interaction Cross Sections for AuNP Surfactant Nuclei vs. Natural 
Gold and Natural Aluminum 
Nuclide 
Thermal 
σ(n,γ) 
(barns) 
I∞ σ(n,γ) 
(barns) 
Thermal σs 
(barns) 
Fis. 
Spectrum 
Avg. σs 
(barns) 
23
Na 0.53 0.311 3.024 3.142 
12
C 0.0035 0.0015 4.746 2.363 
1
H 0.332 0.149 20.47 3.926 
16
O 0.00019 0.000085 3.780 2.742 
198
Au 98.65 1550     
27
Al 0.231 0.14   
 
 
 
3.3 Changing AuNP Size and Surface Energy 
 The surfaces of all materials have a certain degree of “surface energy”.  Surface 
energy can be defined as the work required removing a molecule from bulk to surface, or 
the degree to which the surface of a material is in an excited state in comparison to the 
bulk.  Surface energy can be better understood using Figure 3.5 below.   
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Fig. 3.5:  The Surface of a Material with Dangling Bonds (Top) [71] 
 
As shown in Figure 3.5, the surface of any material is not bound in all directions, 
resulting in “dangling bonds” (top).  These dangling bonds reside in a high energy state.  
A form of surface restructuring can take place, which could produce lattice dislocations, 
voids, or other thermodynamically unfavorable phenomena [72]. In the macroscopic 
world we do not notice surface energy due to the extremely small fraction of object’s 
atoms which lie on the surface.  For materials in the nano-scale regime, however, surface 
energy is much more noticeable. 
Assuming gold has a surface energy density of approximately 1 J m
-2
, the surface 
energy of gold nanoparticles based on size can easily be calculated [73].  Table 3.2 
below illustrates the size-dependent surface energy for three 1 g samples of gold spheres 
with arbitrary radii of (a) 1 mm, (b) 50 nm, and (c) 8 nm.  Note that if the AuNPs were 
50 nm in radius rather than 8 nm, the surface energy decreases by a factor of 6.25. 
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Table 3.2:  Size-dependent Surface Energy for 1 g of Three Different Sized Gold 
Spheres 
Radius (cm) # AuNPs Total Surface Energy (J) 
0.1 1.2E+01 1.5E-04 
5.00E-06 9.9E+13 3.1 
8.00E-07 2.4E+16 19.4 
 
 Higher AuNP surface energy increases the attraction between adjacent 
nanoparticles, preferentially driving agglomeration.  Researchers suggest that 100 nm 
approaches the upper limit of AuNP size which can still traverse the cell membrane of 
many types of cancer cells [31].  Using a 100-nm diameter AuNP rather than a 17-nm 
diameter AuNP will help mitigate agglomeration issues during neutron activation due to 
its lower surface energy. 
We purchased the 100 nm AuNPs from Cytodiagnostics to study surfactant 
stability compared to the 10 nm Nanopartz sample.  Since 100-nm AuNPs have a much 
larger surface area to which mAbs may attach and therefore many more attached 
antibodies per nanoparticle, directional mAb conjugation is less critical.  Non-directional 
conjugation is simple; the mAbs will undergo passive adsorption to the AuNP surface 
mediated by their respective electrostatic and hydrophobic interactions.  Antibody 
adsorption to AuNPs is most successful at or around the isoelectric point of the antibody 
of interest (the pH at which the antibody carries no electrical charge).  Fortunately the 
isoelectric point of PE CD340 is 7.2, which is almost exactly the pH of the stock 100 nm 
AuNP mixture provided by Cytodiagnostics, and close to that of water.  This implies that 
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buffers for pH titration and optimization may not be necessary.  In order to reach 
conjugation saturation, the mAb:AuNP ratio was no less than 1 μg of pure CD340 mAb 
per 100 μL of stock AuNP mixture (or 3.84E8 AuNPs since the stock solution had a 
density of 3.84x10
9
 AuNPs mL
-1
).  Knowing that CD340 weighs approximately 185 kD, 
this yields a mAb:AuNP molar mixing ratio of about 8500:1.  The CD340 provided by 
Biolegend was already sufficiently diluted such that a mixing ratio of 1 mL of mAb 
stock solution to 1 mL of AuNPs stock mixture yielded a mAb:AuNP molar ratio of 
about 10,600:1.  This mixture was gently stirred using a vortex machine at 4 °C 
overnight to drive the conjugation reaction.  The sample was centrifuged for 10 minutes 
at 400x RCF and the supernatant was extracted; 2 mL of triple-distilled water was added 
such that the sample contained only conjugated AuNPs in water. 
To ensure successful antibody attachment and appropriate pH conditions, we 
added 100 μL of 10% NaCl solution to the conjugated AuNPs.  According to the vendor, 
if the conjugation conditions were suboptimal, the NaCl would have induced 
aggregation and changed the color of the mixture to the naked eye.  The addition of 
NaCl had no effect, suggesting that the above conjugation methods were successful. 
 
3.4 Changing Reactor Conditions 
 One additional method to mitigating AuNP agglomeration during neutron 
activation is to use a nuclear reactor with a much larger neutron flux.  The 1 MW TAMU 
NSC nuclear reactor has a neutron thermal flux of approximately 10
13
 n s
-1
 cm
-2
.  If we 
have access to a nuclear reactor with a thermal neutron flux of about 6x10
14
 n s
-1
 cm
-2
.  
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With a flux this large, it may be possible to significantly reduce AuNP activation time.  
If such a high flux reactor also maintains a lower full power primary coolant outlet 
temperature (Thot), this could also improve the likelihood of surfactant survival. 
 Utilizing activation methods/reactors outside of TAMU is currently outside the 
scope of this project.  It may be possible, however, to prevent irreparable agglomeration 
during 100 nm AuNP activation in the TAMU NSC reactor due simply to the larger 
particle size.  The 100 nm AuNPs are composed of many more gold nuclei, and will 
therefore contain more radioactive atoms per nanoparticle compared to 10 nm AuNPs 
under identical activation conditions.  This will allow us to activate the nanoparticles for 
a much shorter period of time while maintaining the requirement that every nanoparticle 
must contain radioactive atoms.  If agglomeration is apparent but minimal due to this 
shorter activation time, the nanoparticles may be sonicated to potentially re-disperse 
them.  Furthermore, subsequent nanoparticle activations will not incorporate aluminum 
foil padding (see Figure 2.3).  This will decrease the gamma decay dose from the 
radioactive isotope 
28
Al.  Although the added aluminum foil is relatively transparent to 
neutrons (see Table 3.1), a significant quantity of aluminum foil has been present in 
previous activation attempts.  Considering 
28
Al decays are accompanied with 1.779 MeV 
gamma rays with an intensity of 100% and a half-life of approximately 2.24 minutes, 
gamma radiation-induced surfactant failure can be slightly reduced by not incorporating 
aluminum foil for subsequent activations.  Other present nuclides may contribute to 
neutron absorption-induced gamma exposure through interactions such as 
23Na (n,γ) 
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24
Na, however interactions which involve surfactant nuclides are unavoidable as they are 
crucial to nanoparticle anticoagulant stability. 
 
3.5 Calculated Radioactive Nuclei per 100 nm Diameter Nanoparticle 
 As previously discussed, we postulate that a lower limit of nano-TRT treatment 
efficacy requires that each nanoparticle have at least one radioactive atom in order for 
the AuNP to provide radiotherapeutic effect (see page 25).  When using a 100 nm 
diameter AuNP instead of 10 nm, NAA shows that the average number of radioactive 
atoms per AuNP may be increased dramatically even while activating the nanoparticles 
for a much shorter period of time.  Activating 100 nm AuNPs in the TAMU NSC reactor 
for 1 hour yields an average of about 161 radioactive atoms per nanoparticle (after 24 
hours of decay, this will be approximately 124 radioactive atoms per nanoparticle), that 
is significantly higher than that of using 10 nm AuNPs (nearly 85% of these 
nanoparticles would not contain any radioactive atoms after 1 hour of activation).  
Figure 3.6 below shows the Poisson probability distribution of radioactive atoms (
198
Au) 
per 100 nm nanoparticle when activated for 1 hour in the TAMU NSC nuclear reactor 
(and allowed to decay for 24 hours). 
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Fig. 3.6:  Discrete Poisson Distribution of Calculated 
198
Au Nuclei per 100 nm Diameter 
AuNP Given tirr = 1 h, and td = 24 h in TAMU NSC Nuclear Reactor 
 
While it is likely that there will be fewer nanoparticles per cancer cell, each 
nanoparticle now has orders of magnitude more radioactive nuclei.  Based on the 
activation conditions shown in Figure 3.6, the average nanoparticle contains 
approximately 124 radioactive atoms.  Again assuming infinite AuNP residence time, 
and the dose from the primary β- emission to cancerous tissue vs. 100 nm AuNPs per cell 
is shown below in Figure 3.7. 
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Fig. 3.7:  Calculated Dose (Gy) from Primary β- Emission of TAMU NSC-Activated 
100 nm AuNPs vs. 100 nm AuNPs per Cell, Given tirr = 1 h, and td = 24 h, Assuming 
Infinite AuNP Residence Time Approximation 
 
3.6 Final AuNP Activation: 100 nm Diameter without Aluminum Foil 
 Previous attempts to produce radioactive AuNPs (both 10 nm and 17 nm) ended 
in surfactant failure and irreversible agglomeration.  We hypothesized that decreasing 
the surface energy (by using larger nanoparticles), not filling the activation vessel with 
aluminum foil, and activating for a shorter period of time would prevent surfactant 
failure and agglomeration.  The quartz ampoule survived the activation, and did not 
crack during insertion or removal from the reactor core, suggesting that the aluminum 
foil padding was not necessary.  After one hour of activation and two hours of decay, the 
sample solution had not yet changed color and no particulates were visible, indicating 
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that surfactant failure was negligible to the naked eye.  The sample’s 198Au activity after 
two hours of decay was about 50 µCi, and the 
24
Na activity (which has a half-life of 
about 15 hours, compared to 
198
Au’s 2.69 days) was about 0.14 µCi.  We had intended to 
conduct TEM or AFM to further characterize the AuNPs after activation; however, the 
project was canceled immediately after this activation despite its success.  Subsequently, 
sample characterization followed by nano-TRT cell treatment was not carried out. 
 
3.7 Flow Cytometry Characterization 
 Our initial supply of antibodies was small, and we were unable to purchase more 
due to lack of funding.  We had to experiment with the mAbs sparingly.  Before doing 
so, however, we explored flow cytometry with 10 nm AuNPs, 100 nm AuNPs, and SK-
BR-3 cells to establish control groups.  As shown below in Figure 3.8 and Figure 3.9, the 
absorption spectra of the two different sized nanoparticles differ considerably.  The 
absorption/emission spectrum of PE is also shown in Figure 3.10.  The Accuri C6 Flow 
Cytometer excitation lasers (488 nm and 640 nm) have been superimposed onto the 
figures.  Note that the concentrations of 10 nm AuNPs mL
-1
, 100 nm AuNPs ml
-1
, and 
PE-CD340 mAbs mL
-1
 are 5.98x10
12
, 3.84x10
9
, and 4.07x10
13
, respectively. 
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Fig. 3.8:  Absorbance vs. Excitation Wavelength Spectrum of 10 nm AuNPs 
(Cytodiagnostics) Using UV-Vis Spectroscopy, with Accuri C6 Flow Cytometer 
Excitation Lasers (488 nm in Blue, 640 nm in Red) Superimposed 
 
 
 
Fig. 3.9:  Absorbance vs. Excitation Wavelength Spectrum of 100 nm AuNPs 
(Cytodiagnostics) Using UV-Vis Spectroscopy, with Accuri C6 Flow Cytometer 
Excitation Lasers (488 nm in Blue, 640 nm in Red) Superimposed 
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Fig. 3.10:  Absorbance vs. Excitation Wavelength Spectrum of PE CD340 mAbs 
(Biolegend), with Accuri C6 Flow Cytometer Excitation Lasers (488 nm in Blue, 640 
nm in Red) Superimposed [59] 
 
 Both lasers miss the SPR of both 10 nm and 100 nm AuNPs.  The 488 nm laser is 
well within the absorption region (normalized absorbance of about 70%) of the 10 nm 
AuNPs to yield a detectable signal, while the 640 nm laser will yield almost no signal 
(normalized absorbance of about 5%).  The 100 nm AuNPs will absorb both the 488 nm 
laser and the 640 nm laser with normalized absorbance of about 40% and 60%, 
respectively.  Figure 3.11 below shows the flow cytometer forward scattering (FSC) and 
side scattering (SSC) associated with bare 10 nm AuNPs (left) and bare 100 nm AuNPs 
(right).  The 10 nm AuNPs are both older and more concentrated, which may contribute 
to the higher degree of forward scattering and the greater number of counts.  These 
experiments show a clear side scattering trend associated with the nanoparticles.  Note 
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that all flow cytometry experiments were conducted with the same flow conditions for 
the same 5 minute period.  The total number of counts for the 10 nm AuNPs, 100 nm 
AuNPs, and PE CD340 mAbs (see Figure 3.12) were 6,429, 587, and 47,492, 
respectively.  Note that it is difficult to determine mAb attachment per nanoparticle, or 
precise nanoparticle concentration in the conjugated sample (see Figure 3.13) due to 
inefficiencies in removing supernatant; however the conjugated AuNPs yielded 692 
counts. 
 
             
Fig. 3.11:  Flow Cytometry Scattering of Stock Bare 10 nm (Left) and 100 nm (Right) 
AuNPs 
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Fig. 3.12:  Flow Cytometry Scattering of Stock Bare PE CD340 mAbs 
 
Contrary to the side scattering associated with the nanoparticles, the PE CD340 
mAbs appear to show a large degree of forward scattering, shown below in Figure 3.14.  
We then conjugated the 100 nm AuNPs with PE CD340, whose flow cytometry results 
yielded inconclusive information shown below in Figure 3.13.  If conjugation were 
unsuccessful, we would expect to see the spectrum dominated by bare PE CD340 with 
the bare 100 nm AuNP spectrum superimposed onto it.  This in fact did not occur.  Not 
only does this suggest that something has altered the PE CD340 spectrum (i.e. they may 
now be attached to an AuNP), but our attempts to remove the supernatant were relatively 
successful.  The 100 nm AuNPs are quite large, and the SPR can dramatically increase 
the total photon interaction cross section of materials (as compared to bulk) based on 
particle size and excitation wavelength. 
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Fig. 3.13:  Flow Cytometry Scattering of PE CD340-Conjugated 100 nm AuNPs 
 
 We had intended on exploring flow cytometry by treating SK-BR-3 cells with 
conjugated AuNPs, unconjugated AuNPs, and mAbs alone; however sufficient 
antibodies were not available.  The SK-BR-3 cells do indeed have a distinct scattering 
spectrum (Figure 3.14), however, which suggests that these experiments may yield 
useful information. 
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Fig. 3.14:  Flow Cytometry Scattering of SK-BR-3 Cancer Cells Alone 
 
3.8 Gel Electrophoresis Characterization and mAb-AuNP Conjugation 
 The experiments in the previous section suggest that flow cytometry does not 
yield conclusive evidence of mAb-conjugated 100 nm AuNPs with these spectra, so 
other methods to determine conjugation were explored.  The first experiment using gel 
electrophoresis was conducted simply to observe bare AuNP response to electrophoresis 
as a function of size.  Shown in Figure 3.15 below from left to right, lanes 1-5 are bare 
10 nm AuNPs (Cytodiagnostics), lanes 6-10 are bare 100 nm AuNPs (Cytodiagnostics), 
and lanes 11-15 are PE CD340 alone.   
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Fig. 3.15:  Agarose Gel Electrophoresis with Bare 10 nm AuNPs (Lanes 1-5), Bare 100 
nm AuNPs (Lanes 6-10), and PE CD340 Alone (Lanes 11-15) 
 
Figure 3.15 is the original image which may be difficult to see due to the bright 
signal from the PE CD340.  Figure 3.16 below shows this image without lanes 11-15 to 
resolve contrast, which may be easier to see the AuNPs more distinctly.  Note that the 
100 nm sample is less concentrated, which accounts for the weak signal.  This simple 
experiment revealed that bare 10 nm AuNPs are small enough to travel through the 
agarose gel under these conditions, while the bare 100 nm AuNPs are too large to do so. 
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Fig. 3.16:  Figure 3.15 with Resolved Contrast; Bare 10 nm AuNPs (Lanes 1-5), Bare 
100 nm AuNPs (Lanes 6-10), and Lanes 11-15 Cropped Out 
 
 We replicated the previous electrophoresis experiment with 100 nm AuNPs 
(Cytodiagnostics), both bare and mAb-conjugated.  Recall that CD340 is tagged with 
PE, which has spectral properties similar to that of the fluorophore Cy3 (see Figure 
2.13).  Shown below in Figure 3.17, lanes 1-5 contain 100 nm AuNPs conjugated with 
PE CD340, lanes 6-10 contain bare 100 nm AuNPs, and lanes 11-15 contain PE CD340 
alone. 
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Fig. 3.17:  Agarose Gel Electrophoresis with PE CD340-Conjugated 100 nm AuNPs 
(Lanes 1-5), Bare 100 nm AuNPs (Lanes 6-10), and PE CD340 Alone (Lanes 11-15) 
 
 This experiment reveals several important features.  Comparing Figures 3.15 and 
3.16 (lanes 1-10) with 3.17 above (lanes 6-10), it is again obvious that the larger size of 
the 100 nm AuNPs retards their travel through the gel such that, under identical 
operating conditions, the bare 100 nm AuNPs barely moved in comparison to the 10 nm 
AuNPs.  Figure 3.17 also strongly suggests that the AuNPs in lanes 1-5 are indeed 
conjugated since the AuNPs in lanes 1-5 (dark black rectangles) moved much further 
than the bare AuNPs in lane 6-10.  The bright shapes on the left in lanes 1-5 are 
consistent with the PE CD340 antibodies in the right in lanes 11-15, indicating that our 
PE CD340-
Conjugated 100 nm 
AuNPs 
Remaining PE CD340 
Supernatant 
PE CD340 Control 
Bare 100 nm AuNP Control 
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attempt to fully remove the remaining unconjugated mAb supernatant was not perfect.  
See Figure 3.18 for resolution-resolved views of lanes 1-5 (left), 6-10 (middle), and 11-
15 (right). 
 
   
Fig. 3.18:  Close-Up Resolution-Resolved Views of Lanes 1-5 of Fig. 3.19 with PE 
CD340-Conjugated 100 nm AuNPs (Left), Lanes 6-10 of Fig. 3.19 with Bare 100 nm 
AuNPs (Middle), Lanes 11-15 of Fig. 3.19 with and PE CD340 Alone (Right) 
 
3.9 Cytotoxic Effects of Non-Radioactive AuNPs 
 We decided to explore the cytotoxic effect of non-radioactive AuNPs in SK-BR-
3 cancer cells by introducing various concentrations of AuNPs to cells and observing 
cellular response as a function of time using the xCELLigence system.  Our system is an 
8x2 (16-well) plate for which the wells are defined as shown below in Figure 3.19 and 
loaded with 10 μL incremental titrations of increasingly dilute AuNP mixture yielding 
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the concentrations shown in Table 3.3.  Due to the small size of the 10 nm AuNPs, the 
AuNPs are significantly more abundant than cells.  The control group wells H1 and H2 
have no cells or AuNPs.  The cellular response to the AuNP treatment as a function of 
time is shown in Figure 3.20. 
 
Table 3.3:  Non-Radioactive 10 nm AuNP Cytotoxicity Experiment, Well Layout 
Information at Initiation of Treatment 
Well 
ID 
Cell Type Cells Well
-1
 Compound 
Concentration 
(AuNPs Well
-1
) 
Concentration 
(AuNPs Cell
-1
) 
A1 SK-BR-3 120,000 10 nm AuNPs 3.00E+10 250,000 
B1 SK-BR-3 120,000 10 nm AuNPs 1.50E+10 125,000 
C1 SK-BR-3 120,000 10 nm AuNPs 7.50E+09 62,500 
D1 SK-BR-3 120,000 10 nm AuNPs 3.75E+09 31,250 
E1 SK-BR-3 120,000 10 nm AuNPs 1.88E+09 15,667 
F1 SK-BR-3 120,000 10 nm AuNPs 9.38E+08 7,817 
G1 SK-BR-3 120,000 10 nm AuNPs 0 0 
A2 SK-BR-3 120,000 10 nm AuNPs 3.00E+10 250,000 
B2 SK-BR-3 120,000 10 nm AuNPs 1.50E+10 125,000 
C2 SK-BR-3 120,000 10 nm AuNPs 7.50E+09 62,500 
D2 SK-BR-3 120,000 10 nm AuNPs 3.75E+09 31,250 
E2 SK-BR-3 120,000 10 nm AuNPs 1.88E+09 15,667 
F2 SK-BR-3 120,000 10 nm AuNPs 9.38E+08 7,817 
G2 SK-BR-3 120,000 10 nm AuNPs 0 0 
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Fig. 3.19:  Legend for Non-Radioactive 10 nm AuNP Cytotoxicity Experiment, 8x2 
Labeled Wells 
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Fig. 3.20:  Non-Radioactive 10 nm AuNP Cytotoxicity Experiment, Mean (± Standard Deviation) Cell Index vs. Time 
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 The cytotoxic effects of non-radioactive 10 nm AuNPs can be seen above in 
Figure 3.20.  The vertical line at 21 hours 35 minutes of cell growth signifies when the 
non-radioactive 10 nm AuNP treatment was initiated.  While the impact of the 
nanoparticles is noticeable, two conclusions may be drawn with reasonable confidence:  
the cytotoxic effects of non-radioactive 10 nm AuNPs (at least up to concentrations of 
250,000 AuNPs cell
-1
) are non-lethal.  Secondly, over the lifetime of the experiment 
there are variations which may or may not be associated with the nanoparticles at all.  
While the control group that wasn’t treated with any AuNPs (G1 and G2) does have the 
highest cell index as expected, the group which was treated with the highest AuNP 
concentration (A1 and A2) did not show the lowest cell index, indicating random 
variations associated with cell growth.   
This experiment also suggests that the presence of a high density of 10 nm 
AuNPs has little to no effect on the measured impedance of the device.  Prior research 
has shown that AuNP cytotoxicity is a strong function of nanoparticle size, with smaller 
nanoparticles being more cytotoxic; this suggests that cellular response to the 100 nm 
AuNPs will be even less noticeable [74], and will be discussed later in this section. 
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This first 10-nm non-radioactive AuNP cytotoxicity experiment yields 
information which would otherwise would not be observable from a traditional 
clonogenic assay, and can best be illustrated by looking only at the two groups which 
had the highest (A1 and A2) and lowest (G1 and G2) concentrations of gold 
nanoparticles shown below in Figure 3.21.  If the AuNPs caused a noticeable change in 
detector impedance, the rise in wells A1 and A2 would have been permanent.  The cell 
index rises, and then within 10 hours drops down again, indicating a defensive cellular 
response at the beginning of treatment followed by noticeable cytotoxic effects hours 
later.  
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Fig. 3.21:  Non-Radioactive 10 nm AuNP Cytotoxicity Experiment, Mean (± Standard Deviation) Cell Index vs. Time of 
250,000 AuNPs/Cell (Red) and Zero AuNPs/Cell (Green) 
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 We ran an additional experiment with the 100 nm AuNPs from Cytodiagnostics 
to determine gold cytotoxicity changes due to using larger nanoparticles.  See Table 3.4 
and Figure 3.22 below for the concentrations and “Well ID’s” for the 100 nm AuNP 
cytotoxicity experiment. 
 
 
Fig. 3.22:  Legend for Non-Radioactive 100 nm AuNP Cytotoxicity Experiment, 8x2 
Labeled Wells 
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Table 3.4:  Non-Radioactive 100 nm AuNP Cytotoxicity Experiment, Well Layout 
Information at Initiation of Treatment 
Well 
ID 
Cell-Type 
Cells 
Well
-1
 
Compound 
Concentration 
(AuNPs Well
-1
) 
Concentration 
(AuNPs Cell
-1
) 
A1 SK-BR-3 120,000 100 nm AuNPs 3.84E+07 320 
B1 SK-BR-3 120,000 100 nm AuNPs 1.92E+07 160 
C1 SK-BR-3 120,000 100 nm AuNPs 9.60E+06 80 
D1 SK-BR-3 120,000 100 nm AuNPs 4.80E+06 40 
E1 SK-BR-3 120,000 100 nm AuNPs 2.40E+06 20 
F1 SK-BR-3 120,000 100 nm AuNPs 1.20E+06 10 
G1 SK-BR-3 120,000 100 nm AuNPs 0 0 
A2 SK-BR-3 120,000 100 nm AuNPs 3.84E+07 320 
B2 SK-BR-3 120,000 100 nm AuNPs 1.92E+07 160 
C2 SK-BR-3 120,000 100 nm AuNPs 9.60E+06 80 
D2 SK-BR-3 120,000 100 nm AuNPs 4.80E+06 40 
E2 SK-BR-3 120,000 100 nm AuNPs 2.40E+06 20 
F2 SK-BR-3 120,000 100 nm AuNPs 1.20E+06 10 
G2 SK-BR-3 120,000 100 nm AuNPs 0 0 
 
The 100 nm AuNPs were added to the wells at approximately 23.5 hours, shown 
by the collective line humps.  As shown below in Figure 3.23, the cell sample became 
contaminated with bacteria at approximately 38 hours, evident by the drastic increase in 
cell index toward the end of the timeline.  The downward and upward jumps at 
approximately 41.5 hours are a result of opening the incubator and removing the well 
plates for inspection.  The bacteria did not begin to affect the sample significantly until 
at least 14 hours after the 100 nm AuNPs were added to the cell samples.  This suggests 
that even though the samples were contaminated, it also demonstrates that 100 nm non-
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radioactive AuNPs have no cytotoxic effect to the SK-BR-3 cells due to the lack of 
growth rate change before/after treatment administration. 
Wells A-F were all treated with 10 μL of solution with varying AuNP 
concentrations diluted in triple distilled water, and wells G1-G2 were treated with 10 μL 
of pure triple distilled water as a control.  Figure 3.23 clearly shows that wells G1 and 
G2 were not contaminated with bacteria while wells A-F were.  This indicates that the 
water used to dilute the AuNP mixture was not contaminated, and further reveals that 
our treatment procedures were successfully executed in a sterile manner.  Therefore the 
stock 100 nm AuNP mixture from the vendor itself may be contaminated with bacteria.  
As a result, subsequent experiments with this batch of nanoparticles will first be treated 
with penicillin prior to combining with the cells to kill any bacteria which may be in the 
stock AuNP mixture. 
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Fig. 3.23:  Non-Radioactive 100 nm AuNP Cytotoxicity Experiment, Mean (± Standard Deviation) Cell Index vs. Time 
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3.10 AuNP Endocytosis 
 Figure 3.21 shows a clear cellular response due to treating with non-radioactive 
AuNPs.  One likely cause of this phenomenon is a process called endocytosis, where the 
nanoparticles with pass through the cell membrane by one of several various “engulfing” 
mechanisms [75].  The optimal AuNP size for Trastuzumab-conjugated nanoparticles to 
maximize cancerous AuNP endocytosis is 50 nm in diameter [76].  Conjugated AuNP 
endocytosis enters the cell through receptor-mediated endocytosis, shown below in 
Figure 3.24 [76].  The key factors which influence this process are the size, shape, and 
charge of the nanoparticle, the conjugation density and orientation, the cellular receptor 
expression levels, and cellular response mechanisms.  
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Fig. 3.24:  Illustration of Receptor-Mediated Nanoparticle Endocytosis [76] 
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4. DERIVATION OF TRT DOSIMETRY USING PROBABILITY THEORY 
 
The ultimate objectives of this derivation are (1) to calculate how many 
radioactive atoms per AuNP are required to produce a desired dose to tumors of varying 
size, and (2) to calculate the resulting dose to surrounding healthy tissue.  There are 
several ways to calculate these doses [77].  Alternatively, one common method to 
determine the degree with radiation effects tissue is to generate a code using a computer 
program, such as MCNPX, and run it a large number of times to simulate the particles 
depositing energy as they travel through tissue.  For this research, however, we have 
chosen to calculate these dose distributions by using probability theory, specifically the 
manipulation of nested multivariable trigonometric weight functions.  This method is 
advantageous in that probability distribution functions (PDFs) can be easily retrofitted 
with pharmacokinetic data specific to the patient or cancer type, allowing a simple 
coupling of pharmacokinetics and dosimetry [78, 79].  For a simple 2-dimensional 
example of manipulating weight functions, see the Appendix.   
 
The pharmacokinetics associated with nano-TRT may depend on several factors 
that may dramatically affect the nanoparticle distribution in the patient’s body.  For this 
reason, we derive a general formula which can be used to calculate the doses to healthy 
and cancerous tissue.  We demonstrate its applicability by considering AuNPs which are 
inside of or attached to cancer tissue for this derivation.  Not all AuNPs may be attached 
to or inside cancerous tissue; however, this is dependent upon pharmacokinetics and can 
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be accounted for using appropriate probability distributions.  To simplify the equations 
involved in this example, we have assumed that the tumors and cells are approximately 
spherical in shape, and that the AuNPs are isotropically distributed within the tumor.  
We also approximate an isotropic AuNP distribution within individual cancer cells 
(important if individual cancer cells such as leukemia are treated and the AuNPs are 
endocytosed) assuming the AuNP movement within the cytoplasm is random [80, 81].  
Emission occurs from within the nanoparticles; however, because the nanoparticles are 
sufficiently small, we approximate that the AuNPs are points rather than spheres, 
ignoring AuNP self-shielding and dose enhancement effects as emissions exit the 
nanoparticle.  We also assume that cancerous tissue and healthy surrounding tissue are 
physically identical, and tissue density is constant; this may not be true for tumors in or 
very close (within a few millimeters) to bone or other dense deposits. 
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Fig. 4.1:  Schematic of Radioactive AuNP Geometry inside Cancerous Cell/Tumor 
 
        (Eq. 4.1) 
  √         ( )      ( ) 
 
 When the conjugated AuNP is located inside the cancerous cell/tumor, the 
geometry of the AuNP, cell/tumor, and β emission path is illustrated by Figure 4.1 
above.  The path length of the β- emitted by the AuNP can be calculated using the law of 
cosines (Equation 4.1, solved for variable “ ”) where... 
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  = the radius of the cancerous cell/tumor 
  = polar β emission angle with respect to the closest outer edge point of the boundary 
  = AuNP distance from the center of the cancerous cell/tumor at the time of decay 
  = the length of cancerous tissue the β emission must traverse to exit the cell/tumor 
      
      
       
 
 Because of spherical symmetry, all points at distance “r” from the center can be 
rotated to the position shown in Figure 4.1 with no loss of generality.  Note that with the 
given assumptions the mathematics are the same for both tumors and individual cancer 
cells; the only difference is the radius of the sphere, “ ”.  With these conventions, if the 
β emission occurs at an angle of    , then the β particle travels directly away from the 
center of the cell/tumor, thereby taking the shortest path possible to reach surrounding 
healthy tissue.  If the β emission occurs at an angle of     radians, then the β particle 
travels directly toward the center of the cell/tumor.  In cases of treating both individual 
cancer cells (such as leukemia) and treating solid tumors, the probability distribution of 
AuNPs located a distance “r” away from the center of the cell/tumor is not constant.  In 
order to account for this, we must apply the weight function ( ), which is a 
mathematical device used when performing sums, integrals, or averages to give some 
elements more “weight” or influence on the result than other elements.  This is discussed 
in the next section. 
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4.1 Tumor Dosimetry Derivation of Endocytosed Nano-TRT 
 We used probability theory to determine the ratio of dose deposited to cancerous 
tissue vs. dose to surrounding healthy tissue.  Deriving these doses is complicated by the 
fact that β particles are not always emitted with the same energy, as shown earlier in 
Figure 1.8.  The β particle range through tissue is therefore a distribution as well.  β 
range through human tissue is correlated to energy by Equation 4.2 (shown from 0 to 
1000 keV in Figure 4.2 below), where energy is keV and range is µm [82].  This 
relationship is only valid for energies between 20 eV and 2 MeV.  The derivative of 
Equation 4.2 with respect to “Rβ” gives the change in energy per unit length, also known 
as the “stopping power” (Equation 4.3).  Note that β particles lose more energy per 
length traveled at lower energies than at high energies. 
 
            (Eq. 4.2) 
 (  )     (        )
     
          
           
 
                     (Eq. 4.3) 
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 (  )         ∫ (
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Fig. 4.2:  β Range vs. Energy in Human Tissue 
 
 In probability theory, a relative probability distribution function (RPDF) is a PDF 
which may not be normalized, in which case is synonymous with a “weight function”.  
The RPDF of the initial β energy from the decay of 198Au shown in Figure 1.8 from 
Fermi theory of beta decay is complex and unwieldy to integrate.  This RPDF can be 
approximated by a simpler polynomial equation, and the PDF of the range of β’s can 
therefore be directly produced from Equation 4.2, shown below in Equations 4.4 and 4.5 
respectively.  The RPDFs derived from Fermi theory of beta decay are shown in Figures 
4.3 and 4.4 below in blue while the polynomial curves are superimposed in black.  More 
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accurate results could perhaps be achieved by using Fermi Theory rather than a 
polynomial approximation; but for this example, the polynomial approximation is 
sufficient.  The polynomial in Equation 4.4 is only valid from 20 eV to 2 MeV. 
 
 
Fig. 4.3:  
198Au β Energy Distribution and Approximate Polynomial Function 
 
(Eq. 4.4) 
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Fig. 4.4:  
198
Au β Range Distribution and Approximate Polynomial Function 
 
(Eq. 4.5) 
                                                          
                                
          
 
 A weight function is a mathematical device used when performing a sum, 
integral, or average to give some elements more influence or “weight” on the result than 
other elements in the same set.  In discrete probability theory, the average value “ ̅” of 
discrete variable “ ” with associated weight function “ ( )” is given by Equation 4.6 
below.  In the case of continuous functions/variables, the average value “ ̅” of 
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continuous variable “ ” is given by Equation 4.7.  The function “ ( )” can be thought of 
as “what we want to know the average of”; it can be a variable or a function with nested 
variables.        
 
(Eq. 4.6) 
 ̅  
∑ ( ) ( )
∑ ( )
 
           
       
 
      
 
 (Eq. 4.7) 
 ̅  
∫  ( ) ( )   
∫ ( )   
 
 
 A PDF can be defined as a normalized weight function, shown below in Equation 
4.8 where  ( ) is the PDF of variable “ ”.  Note that the “area under the curve” for the 
PDF between the minimum and maximum values of “ ” is equal to one.  This implies 
that the probability of the variable “ ” attaining a value between its minimum and 
maximum bounds is 1, or 100%.   
 
                                       (Eq. 4.8) 
 ( )  
 ( )
∫  ( )
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As an example, given a sphere of radius “ ”, the PDF of the radius inside this 
sphere can be derived using Equation 4.8.  In the context of this problem, “ ” could be 
the radius of a tumor, and “ ( )” can be thought of as the probability of finding a 
nanoparticle a distance “ ” away from the center of the tumor. 
 
 ( )  
 ( )
∫  ( )
    
    
  
 
 
 ( )       
 
 ( )  
    
∫     
 
 
  
 
 
  
    
 
In probability theory, two variables “ ” and “ ” are independent if the following identity 
is true. 
 
 (   )   ( ) ( ) 
 
This identity states that if the probability of a multivariable event   (   ) whose 
outcome is “ ” and “ ” is equal to the product of the probabilities of the two events, 
 ( ) and  ( ), then the two variables “ ” and “ ” are independent.  It should be 
obvious in the context of this problem that the location of the AuNP with respect to the 
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center of the tumor (expressed by variable “ ”) and the angle of β emission (expressed 
by variable “ ”) are independent; i.e. the location of the AuNP does not influence the 
direction of radioactive emission, and vice versa.  Since we are assuming that the 
nanoparticles are distributed in the tumor isotropically with respect to volume, the value 
of the variable “ ” has a non-uniform weight function. 
 The value of interest,  , is given by the law of cosines (Equation 4.1).  
Radioactive emissions are released with no preferential solid angle direction, so the 
weight function for solid angle is therefore unity.  Any solid angle direction, Ω, can be 
expressed in spherical coordinates with the variables “ ” and “ ”, which are the polar 
and azimuthal angles of emission, respectively.  The differential solid angle element 
expressed in terms of “ ” and “ ”, however, is given by       ( )     , shown 
below in Figure 4.5 [83]. 
 
 
Fig. 4.5:  Solid Angle in Spherical Coordinates 
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 If the weight functions for both “ ” and “ ” are equal to “1”, then the 
distribution of emission angles will be incorrectly “bunched” at the poles of the sphere, 
shown below in Figure 4.6 where the left and right spheres are the top and side views, 
respectively [84].  Instead, the weight function for the polar coordinate must be set equal 
to “   ( )”, yielding the expected isotropic solid angle distribution in Figure 4.7, where 
the left and right spheres are the top and side views, respectively [84]. 
 
 
Fig. 4.6:  Incorrect Angular Distribution, with  ( )   ( )    
 
 
 
Fig. 4.7:  Correct Angular Distribution, with  ( )     ( )     ( ) 
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We can first find the average distance the AuNP is located from the center of the 
tumor or cell.  If the AuNP’s location inside the tumor/cell is random and isotropic with 
respect to volume, then the solution is shown below.  This solution should make sense, 
because the volume of the sphere increases with radius by a factor of   , meaning that 
the answer should be between “    ” and “ ”. 
 
 ̅  
∫  ( ) ( )   
∫ ( )   
 
 
 ( )    
 
 ( )      
 
 ̅  
∫ ( )(   )
 
 
  
∫ (   )
 
 
  
 
 
 ̅        
 
 There is no simple “plug in and plot” method to produce the PDF of   with 
respect to   since it is a dependent variable.  In other words,  ( ) is a “function of two 
multivariable functions”.  One could derive  ( ) rigorously by executing a 
transformation of variables (which would probably be necessary for complicated 
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probability distributions associated with pharmacokinetics), but we can simplify things 
in this example by exploiting the symmetry of the sphere with particles located 
isotropically inside of it [85, 86].  In general,  ( ) is defined as the probability 
distribution of distances the β particle must travel through cancerous tissue before 
reaching surrounding tissue.  Specifically for this problem, we can define the following: 
 
 ( )   [                                                    (      )
                                        ] (
 
 
   ) 
 
This volume can be expressed by the equation below, and is illustrated in Figure 4.8.  In 
this case, the differential height “  ” is simply “  ”. 
 
    ∫     
 
 
∫   
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Fig. 4.8: Spherical Volume such that the Distance to the Surface in the Upward 
Direction is between “ ” and “  ” 
 
In order to perform a change of variables, we must now express the radial 
component in terms of “ ”.  Since the maximum value “ ” can attain is the diameter of 
the sphere (or “  ”), and due to the symmetry of the geometry, we can split the sphere 
into top and bottom halves, each with heights “  ⁄ ” (shown below in Figure 4.9).  This 
allows us to express “ ” in terms of “ ” by using the Pythagorean Theorem.  Integrating 
below, the distribution  ( ) becomes Equation 4.9 shown below. 
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Fig. 4.9:  Change of Variables from “ ” to “ ” for Particle Isotropy and Spherical 
Symmetry 
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 (Eq. 4.9) 
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Fig. 4.10:   ( ) vs.   for Particle Isotropy in a Sphere 
 
 Figure 4.10 above is the PDF of  .  One can immediately identify that the 
average distance the β emissions must travel through the tumor is less than the radius of 
the tumor; in other words, the average value of   should be between “ ” and “ ”.  The 
true average value of   is calculated below.  Note that  ( ) is already normalized 
(because it is a PDF), so the denominator is unity. 
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We can verify that the PDF for Figure 4.10 is correct by utilizing the multivariable 
weight functions (Equation 4.5) for “ ”, “ ”, and “ ”, and by expressing “ ” in terms 
these variables by using Equation 4.1, shown below. 
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 The value of  ̅ is again      .  We now have everything required to determine 
the average amount of energy deposited to tumor tissue, which, in turn, can be used to 
directly calculate the energy to healthy tissue.  We can use Equation 4.10 below to 
calculate energy to tumor vs. energy to healthy surrounding tissue ratios, where   ̅̅ ̅ is the 
total average amount of energy the β will deposit to human tissue (both cancerous and 
healthy),   ̅ is the average amount of energy the β will deposit only to cancerous tissue, 
and   ̅̅ ̅ is the average amount of energy the β will deposit only to surrounding healthy 
tissue.   
 
    ̅̅ ̅̅ ̅    ̅̅ ̅            
 
  ̅̅ ̅    ̅̅ ̅    ̅                                              (Eq. 4.10) 
 
 The energy deposited to tumor tissue is a function of (a) how far the β must 
travel through the tumor tissue before reaching healthy tissue (denoted by “ ”), and (b) 
how far the β will travel before coming to rest (which will henceforth be denoted by 
“ ”).  By solving for the average energy deposited into surrounding healthy tissue and 
knowing that the average β will deposit           of energy in total, Equation 4.10 will 
allow us to calculate the ratio of energy to cancerous tissue vs. total energy to 
surrounding healthy tissue; ideally this ratio should be as close to   as possible, meaning 
that all of the dose to the patient is deposited to cancerous tissue. 
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Recall integrating Equation 4.3 relates the β particle’s range through human 
tissue to the energy it will lose slowing down through it.  If we were to ask the question, 
“how much energy does a β emission deposit to human tissue that travels 906 µm before 
coming to rest”, we would integrate Equation 4.3 using the lower and upper bounds of 0 
µm to 906 µm, shown below. 
 
 (  )         ∫     (        )
      
         
    
   
 
              
 
However, we now ask the question, “if the β first must travel through 850 µm of 
cancerous tissue before it reaches the healthy tissue, how much energy will the β deposit 
to healthy tissue as it comes to rest in this case?”; the same procedure is followed, only 
this time it travels 906-850=56 µm through healthy tissue. 
 
 (  )         ∫     (        )
      
         
    
  
 
             
 
The general formula for the energy deposited to surrounding healthy tissue is 
equal to Equation 4.11 below, where “ ” is the distance the   must travel through 
cancerous tissue to reach surrounding healthy tissue, and “ ” is the total range of the   
emission. 
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  (Eq. 4.11) 
 (   )         ∫     (        )
      
         
    
   
 
    
 
We can use Equation 4.9 to calculate the average energy to the surrounding healthy 
tissue, “  ̅̅ ̅”, as follows. 
 
  ̅̅ ̅  
∫ ∫  (   ) ( ) ( )
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 (   )         ∫     (        )
      
         
    
   
 
    
 
The weight functions in this case are PDFs, which are normalized, so the denominator in 
the above equation is unity.  For 
198Au, the β emission can only travel up to 4505 µm 
through unit-density tissue (the upper bound), and since we are looking at only the 
energy deposited to cancerous tissue, its lower bound must be “ ”.  The maximum value 
for “ ” through the sphere is its diameter.  If the tumor diameter is smaller than the 
maximum β path length (4505 µm in the case of 198Au), the equation can be rewritten as 
shown below.  Figure 4.11 illustrates the associated geometry.  The weight functions 
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 ( ) and  ( ) are the usual PDFs of range and tumor path length from Figure 4.4 and 
Equation 4.9, respectively. 
 
  ̅̅ ̅  ∫ ∫  (   ) ( ) ( )
    
 
    
  
 
 
 
 
Fig. 4.11:  Illustration of β Path through Tissue 
 
If the tumor diameter is larger than the maximum β path length, then some of the 
emissions will inevitably deposit 100% of their energy into the tumor.  This can be 
accounted for by calculation the proportion of path lengths which are larger than the 
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maximum β path length.  This value will henceforth be defined as the factor “ ”, shown 
below in Equation 4.12. 
 
  ∫ (
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                                 (Eq. 4.12) 
 
In the case of a tumor whose diameter is larger than the maximum β path length, the 
average energy deposited to healthy surrounding tissue is: 
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The general formula for energy deposited to healthy tissue surrounding a tumor or 
cancer cell is given by Equation 4.13.  For the case of the radionuclide 
198
Au, the 
maximum β range “    ” through unit-density tissue is 4505 µm. 
 
(Eq. 4.13) 
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 The SI unit of dose in radiation dosimetry is the Gray (Gy), which is equal to 1 
joule per kilogram of tissue.  Equation 4.13 must therefore be converted from keV to 
joules.  Assuming the density “ ” of tissue is constant (which may not be the case if, for 
example, cancerous tissue is located in or near bones or other densifications), the mass 
of a tumor is given by: 
 
       
 
 
     
 
The mass of the surrounding healthy tissue is equal to the shell of healthy tissue 
surrounding the tumor multiplied by tumor density, whose outer radius is equal to the 
maximum β travel length, given by Equation 4.14 below.  These tissue geometries are 
illustrated below in Figure 4.12, where the red line is the radius of the tumor “ ” and the 
green line is the maximum β travel length “    ”. 
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    ]                          (Eq. 4.14) 
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Fig. 4.12:  Illustration of Tumor and Surrounding Healthy Tissue 
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 Combining Equation 4.13 with Equation 4.14 yields Equation 4.15, the average dose deposited to healthy tissue 
surrounding cancerous tissue per decay. 
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(Eq. 4.15) 
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Table 4.1 below shows the variability of these distribution functions for different 
sized tumors, including leukemia cells whose average radius is assumed to be 7.5 µm 
[87].  In Table 4.1,         ,       , and        are the doses to healthy tissue, tumor 
tissue, and total to all tissue, respectively.  Tumors A, B, C, and D are spherical tumors 
with radii of 50 µm, 0.5 mm, 5 mm, and 2.5 cm, respectively. 
 
Table 4.1:  Energy Deposition and Dosimetry Ratios of Cancerous vs. Surrounding 
Healthy Tissue Subject to Nano-TRT 
Tumor 
I.D. 
Radius 
Avg. 
Etumor 
(keV) 
Avg. 
Ehealthy 
(keV) 
      
      
 
Leukemia 7.5 µm 11.2 300.2 0.9999988 
A 50 µm 34.4 277 0.99989 
B 0.5 mm 126.4 185 0.9985 
C 5 mm 290.5 20.9 0.988 
D 2.5 cm 303.8 7.6 0.961 
 
 
4.2 Dose as a Function of Radius 
 Table 4.1 yields a logical result when considering energy deposited to tumors of 
varying radius: the larger the tumor, the more average energy deposited to the tumor.  
The average dose to the tumor, however, decreases as the tumor size increases.  Though 
this may seem counterintuitive, it is true since the proportion of healthy/cancerous mass 
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is smaller for smaller tumors, and dose deposited to tissue is not linear with respect to 
tumor radius. 
Tumors B (left) and D (right) are illustrated below in Figure 4.13.  Again, the red 
line is the tumor radius, and the green like is the maximum β travel length denoting 
exposed healthy tissue; i.e. the green lines are the same length in both cases.  Note that 
mass of healthy tissue is much larger than the mass of cancerous tissue in Tumor B, but 
is much smaller in Tumor D.  Dose is defined as energy deposited per unit mass, and 
smaller tumors are associated with a proportionally larger mass of surrounding healthy 
tissue. 
 
 
Fig. 4.13:  Tumors B (left) and D (right) with Exposed Healthy Surrounding Tissue 
 
To better understand nano-TRT dose vs. tumor size, consider a tumor that is 
much larger than the maximum β travel length, such as Tumor D from Table 4.1 (radius 
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of 2.5 cm).  This tumor can be illustrated by Figure 4.14 below.  Each colored circle has 
a radioactive nanoparticle at its center, and the average β emission will reach the edge of 
its colored region.  This means that half of the decays will reach beyond its own colored 
region (i.e. emissions from the green center circle might leak into the red region).  
Emissions which originate in the green, blue, and red circles cannot reach surrounding 
healthy tissue; however, emissions which originate in the yellow circles can reach 
healthy tissue. 
 
 
Figure 4.14:  Illustration of Tumor D Dose vs. Radius 
 
 Emissions which occur in the green, red, or blue region can be thought of as 
being in an infinite medium of cancerous tissue which is populated with isotropically 
distributed radioactive nanoparticles because no boundary is within the range of the β.  
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In this case, the dose with respect to distance is constant because each point is receiving 
even contributions of exposure from all directions.  In other words, if the PDF of finding 
nanoparticles a distance “ ” from the center of the tumor is given by  ( ), and the mass 
with respect to tumor radius is given by “ ( )”, then the dose as a function of radius for 
the center or “bulk” of a large tumor (i.e. green, red, and blue regions) is constant, shown 
below. 
 
 ( )     
 
 ( )     
 
 (     )  
 ( )
 ( )
   
 
 However, radial positions close to the cancer/healthy tissue boundary (i.e. yellow 
circles) will receive exposure from the radially inward direction (cancerous tissue), but 
receive no exposure from the radially outward direction (healthy tissue) because there 
are no radioactive nanoparticles bound to healthy tissue.  The rate at which dose to the 
tumor decreases near the cancer/healthy tissue boundary for a point source is 
proportional to r
-2
 multiplied by a “boundary effects term”,   ( ).  This boundary effects 
term accounts for the fact that β emissions start with a distribution of energies, they have 
a non-uniform stopping power (see Equation 4.3), and pharmacokinetic non-uniformity 
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which may be specific to the tumor of interest.  To summarize, the dose to cancerous 
tissue as a function of radial position for a point source is given by Equation 4.16 below. 
 
 ( )  {
                          (      )
 
  
   ( )        (      )     
                  (Eq. 4.16) 
  
To better understand the implications of these dose distributions, let’s look at two 
different sized tumors which both have uniform nanoparticle distributions.  To make the 
math easier, we have approximated the boundary effects function to be constant (which 
would require all particles to be emitted at the same energy and stopping power to be 
constant).  The tumor radii ( ) with respect to the particles’ range ( ) are chosen 
arbitrarily as follows. 
 
Larger Tumor:         
Smaller Tumor:      
 
The dose as a function of radius is these situations is given in Figure 4.15 for the larger 
tumor and Figure 4.16 for the smaller tumor. 
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Fig. 4.15:  Approximate Dose to Cancerous Tissue vs. Radial Position,        
 
 
Fig. 4.16:  Approximate Dose to Cancerous Tissue vs. Radial Position,     
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 Figures 4.15 and 4.16 suggest that treating a patient based on an “average tumor 
dose” may not be appropriate for treating tumors.  The average dose may be noticeably 
higher than the dose deposited to the outer rim of the tumor in some cases. 
 
4.3 Generic Case Study: 1 cm Diameter Tumor 
   XRT inevitably subjects healthy tissue to radiative assault since the beam must 
first travel through healthy tissue to reach the cancerous tissue [88].  The appropriate 
dose for primary tumors using XRT is generally less than 100 Gy, while an acceptable 
dose level to tissue outside the tumor is between 5-50 Gy [89].  Some areas of the body 
are more sensitive to radiation than others; for tumors near the pelvic region, for 
example, risk of major complications increases at doses above 40 Gy (at 2 Gy per 
fraction) [90].  XRT fractionation means that the total dose is spread out over several 
small treatments.  The lethal potential of radiation is not only a function of dose, but how 
long it takes to deliver the dose [91-94]. 
If we intend to treat a 1 cm diameter tumor with an average dose of 40 Gy (as 
done currently in practice) using nano-TRT, we need to know the dose deposited to 
surrounding healthy tissue, the total number of AuNPs used, the 
198
Au distribution 
among the AuNPs, and the activation time required to produce this distribution.  The 
first step is to determine how much dose the surrounding healthy tissue receives for this 
treatment (which was derived in chapter 4.1).  According to Table 4.1, a 1 cm diameter 
tumor receives 98.8% of the total dose using nano-TRT (Tumor C), assuming a uniform 
nanoparticle distribution.  Therefore, if the tumor is to receive an average dose of 40 Gy, 
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the total average dose must be 40.48 Gy.  The healthy tissue surrounding this tumor will 
receive an average dose of only 0.48 Gy. 
Assuming a tissue density of 1 g cm
-3
, the mass of surrounding tissue is 
approximately 3.07*10
-3
 kg, and the average energy deposited to the healthy tissue per 
decay is about 20.9 keV, or about 3.35*10
-15
 J.  Given the mass and dose, the total 
energy can be calculated; if the surrounding healthy tissue has a mass of 3.07*10
-3
 kg 
and will receive a dose of 0.48 Gy, a total energy of 1.474*10
-3
 J is required.  Dividing 
the total required energy by the average amount of energy deposited per decay yields the 
number of decays required to deposit this dose, which in this case is 
(            ) (                 ⁄ )  ⁄          decays.  Again assuming that 
the drug has a residence time of about 3 weeks, we can calculate the necessary initial 
number of 
198
Au atoms we need to produce by noticing that 3 weeks is over ten times 
longer than the radioactive half-life of 
198
Au (2.69 days).  This allows us to approximate 
that all          radioactive atoms will have decayed within the 3 week residence time. 
Assuming a 50 nm diameter AuNP (to maximize receptor-mediated nanomaterial 
endocytosis discussed in Chapter 3), we can now choose how many radioactive atoms 
per nanoparticle we wish to have (on average), which will yield the number of AuNPs in 
total.  We have arbitrarily chosen an average of 22 radioactive atoms per AuNP, which 
will require 2*10
10
 AuNPs.  Using Poisson statistics from Chapter 2.5, the distribution of 
198
Au per 50 nm diameter AuNP is shown below in Figure 4.17.  Based on neutron 
activation analysis (Chapter 2.3), an activation time of 1.2 hours is required to produce 
these nanoparticles in the TAMU NSC nuclear reactor. 
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Fig. 4.17:  Distribution of 
198
Au Nuclei per 50 nm AuNP for General Case Study 
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5.  FUTURE WORK 
 
 Two primary avenues for future work are necessary for the continuation of this 
research: (1) the production of radioactive gold nanoparticles must be optimized, and (2) 
time-dependent quantification of the pharmacokinetics of conjugated nanoparticles must 
be quantified defined. 
 The AuNP activation procedures must be optimized to minimize surfactant 
failure and AuNP agglomeration.  It is possible to activate 100 nm AuNPs by irradiating 
the samples at full reactor power for one hour or less using the TAMU NSC reactor.  It 
may be possible to further reduce γ exposure to the surfactant by surrounding the sample 
with a lead shield. 
 A promising alternative to the procedures above is to use the TAMU NSC reactor 
to activate small pure gold foils, then dissolve the radioactive foils and synthesize 
AuNPs in a radiochemistry laboratory [95].  Alternatively, solution samples of 
HAuCl4 could be activated, and then radioactive AuNPs could be directly synthesized 
and coated with a citrate stabilizing agent.  Since the nanoparticles are synthesized after 
neutron activation in this manner, the high temperature/radiative fluence environment 
inside the nuclear reactor cannot compromise the surfactant and is of no concern.  
Furthermore, the gold can be activated much closer to saturation without agglomeration 
concerns.  The synthesis of radioactive citrate-stabilized nanoparticles can be carried out 
by chemical means in a radiochemistry laboratory as follows.  Add 20 mL of 1.0 mM 
HAuCl4 to a 50 mL beaker or Erlenmeyer flask on a stirring hot plate.  Use a magnetic 
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bar to stir the solution and bring the solution to a boil.  Add 2 mL of a 1% solution of 
trisodium citrate dihydrate (Na3C6H5O7
.
2H2O) to the boiling/stirring solution.  The gold 
sol gradually forms as the citrate reduces the gold (III).  Remove from heat when the 
solution has turned deep red or 10 minutes has elapsed. 
Each method of producing radioactive gold nanoparticles has respective costs 
and benefits.  Purchasing the nanoparticles from a vendor and activating them in a 
nuclear reactor is inherently simpler and less time-consuming as the nanoparticles are 
already formed, and the cost is cheaper due to the cost of reagents used to synthesize 
large quantities of gold nanoparticles.  However, avoiding surfactant failure due to the 
high temperatures and high radiative fluence found inside the NSC reactor is a major 
benefit of synthesizing the nanoparticles after neutron activation.  Funding and time 
were key factors when deciding which approach to take for this project, so we decided to 
purchase the nanoparticles from a vendor. 
One additional possibility for the production of large samples of radioactive 
AuNPs is to solicit the use of a higher flux nuclear reactor.  The Missouri University 
Research Reactor (MURR), for example, has a thermal neutron flux of 6x10
14
 n s
-1
 cm
-2
 
(compared to the NSC’s 1013 n s-1 cm-2).  Furthermore, the MURR operates at a Thot of 
58 °C (compared to the NSC’s 80 °C). 
When using a nuclear reactor with a higher flux such as MURR and activating 
for only 10 minutes (allowing 24 hours of decay to ship across state lines back to our 
lab), Figure 5.1 below represents the Poisson distribution which estimates the discrete 
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probability distribution of radioactive atoms (
198
Au) per 100 nm nanoparticle, followed 
by the dose to cancerous tissue in Figure 5.2. 
 
 
Fig. 5.1:  Discrete Poisson Distribution of Calculated 
198
Au Nuclei per 100 nm Diameter 
AuNP Given tirr = 10 min, and td = 24 h in the MURR 
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Fig. 5.2:  Calculated Dose (Gy) from Primary β- Emission of MURR-Activated 100 nm 
AuNPs vs. 100 nm AuNPs per Cell, Given tirr = 10 min, and td = 24 h, Assuming Infinite 
AuNP Residence Time Approximation 
  
0
200
400
600
800
1000
1200
1400
1600
1800
0 2 4 6 8 10 12 14
D
o
se
 (
G
y
) 
100 nm AuNPs per Cell 
 
 
 
116 
 
6.  SUMMARY 
 
 Controllable mechanisms of surfactant failure include (1) the high temperature 
environment, and (2) the high-fluence bombardment of high energy γ-radiation.  The 
effects resulting from these conditions may be ameliorated by using a lower temperature 
nuclear reactor, by employing lead shielding around the sample, or by reducing 
activation time.  Though neutrons and γ rays inevitably interact with and damage 
surfactant nuclei, we successfully activated AuNPs without causing surfactant failure by 
using larger 100 nm diameter AuNPs, which have a lower surface energy and are 
composed of many more nuclei compared to 10 nm and 17 nm AuNPs.   
The larger nanoparticles required significantly less activation time than the 
smaller nanoparticles (1 hour down from at least 6 hours) to meet the criterion of having 
at least 1 radioactive atom per nanoparticle even after several hours of decay.  The 100 
nm AuNP surfactant appeared to survive the 1 hour neutron activation in the TAMU 
NSC nuclear reactor to the naked eye; however, further characterization could not be 
executed due to project cancellation. 
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 We provided a method to calculate the number of radioactive atoms per 
nanoparticle using the Poisson distribution.  By using the xCELLigence system, we 
demonstrated a method of comparing nano-enhanced TRT with other treatments as a 
function of time, though these experiments were not carried out.  The derivation of the 
efficacy of nano-TRT includes dose distributions to cancerous vs. surrounding healthy 
tissue when using nano-TRT.  If pharmacokinetic probability distributions are available, 
the general formula for dose to cancerous vs. healthy surrounding tissue (Eq. 4.15) is 
applicable to any size tumor and any radionuclide.  
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APPENDIX 
 
A.1 1-D Weight Function – Throwing Darts at a Dart Board 
 If we are throwing darts at a dart board of radius “R” and the impact location of 
the dart onto the board is random and isotropic with respect to area, the average location 
of impact is the center of the dart board (   ).  If we instead ask, “what is the average 
distance between the bull’s-eye (the center of the dart board) and the locations the darts 
land”, the answer is different; it cannot be “   ” in this case, because that would 
require that every single dart hit the bull’s-eye.  We must now consider the weight 
function which describes the relative probability of the dart landing a distance “ ” from 
the bull’s-eye.  In general, “ ( )” can be thought of as “what you are looking to find the 
average of”.  The solution to the problem is shown below.  This solution should not be 
surprising, because the circumference on the dart board increases with radius by a factor 
of  , meaning that the answer must be between “    ” and “ ”. 
 
 ̅  
∫  ( ) ( )   
∫ ( )   
 
 ( )    
 ( )      
 ̅  
∫ ( )(   )
 
 
  
∫ (   )
 
 
  
 
 ̅        
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A.2 1-D Nested Weight Function – Cosine 
 In this example we will calculate the average value of the cosine function from 0 
to π radians.  This problem is different from the previous examples in two ways: (1) the 
independent variable is nested within a function of “what we are looking to find the 
average of”, i.e. the angle is nested within the cosine function, and (2) there is no 
preference to angle; i.e. the angle is isotropic, with all angles having the same weight.  
The solution may then be calculated as follows. 
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